

**DAVID G. BOSTWICK, M.D., M.B.A., F.C.A.P.**

**PRESENT ACADEMIC RANK AND POSITIONS**

Chief Executive Officer and Chief Medical Officer,  
American International Biotechnology (AIBioTech) Richmond, VA.  
([www.aibiotech.com](http://www.aibiotech.com))  
Medical Director, AIBioTech LLC in Georgia.  
Associate Medical Director, Bostwick Laboratories, Orlando, FL.  
([www.bostwicklaboratories.com](http://www.bostwicklaboratories.com))

**EDUCATION**

College	University of Maryland: B.A., Biological Sciences; 5/75
Medical	University of Maryland School of Medicine; M.D; 5/79
Internship	Stanford University Medical Center; 7/79 – 7/80
Residency	Stanford University Medical Center; 7/80 – 7/81
Fellowship (Surgical Pathology)	Stanford University Medical Center; 7/81 – 7/82
Research Fellowship	Stanford University Medical Center; 7/82 – 7/84
Management	Loyola College of Maryland; M.B.A., Business Administration; 5/91

**MEDICAL LICENSURE/BOARD CERTIFICATION**

Florida 2002 – Present (ME 86147J)  
Arizona: 2002 – Present (29968)  
Virginia: 1999 – present (0101059208)  
Maryland: 1979 – Present (D23914)  
Massachusetts 2009 (239300)  
New York 2006 – Present (242383)  
Tennessee 2008 – Present (43139)  
New Jersey 2009 (25MF00089600)  
United Kingdom (6166356)  
Diplomat, American Board of Pathology (Anatomic): 1985

## PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

Summer 1976	Biologist, National Cancer Institute, National Institutes of Health, Bethesda, MD
Summer 1977	Faculty Biologist, University of California, San Diego, and the Salk Institute
1979 – 1984	Department of Pathology, Stanford University Medical Center, Stanford, CA
1984 – 1986	Assistant Professor, Laboratory of Surgical Pathology, Department of Pathology, The University of Chicago Hospitals & Clinics, Chicago, IL
1986 – 1991	Chairman, Department of Pathology, Mercy Medical Center, Baltimore, MD Associate Professor of Pathology Department of Pathology, University of Maryland School of Medicine, Baltimore, MD Adjunct Professor of Medical Technology, Loyola College, Baltimore, MD
1991 – 1999	Consultant and Professor of Pathology and Urology, Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Medical School, Rochester, MN
1999 – 2000	Pathologist-in-Chief, Virginia Urology Center, Richmond, Virginia
1999 – 2001	Pathologist-in-Chief, Urology of Virginia, Norfolk, Virginia
1999 – 2011	Chief Executive Officer, Bostwick Laboratories
1999 – 2013	Chief Medical Officer, Bostwick Laboratories
2013 – Present	Assoc. Medical Director
2009- Present	Chief Medical Officer, American International Biotechnology
2013- Present	Chief Executive Officer, American International Biotechnology
2013- Present	Managing Partner, Medication Control Systems

## **PROFESSIONAL MEMBERSHIPS AND SOCIETIES**

American Association for the Advancement of Science (AAAS) (1993 – 2000)  
American Association of Blood Banks (AABB) (1986 – 1991)  
American Association of Pathologists (AAP) (1984 – 1993)  
American College of Physician Executives (ACPE) (1992 – 2002)  
American Society of Clinical Pathology (ASCP) (1993 – present)  
American Urological Association (AUA) (1997 – present)  
Arizona Cancer Center (ACC) (2000 – 2009)  
Baltimore City Medical Society (1989 – 1991)  
BJU International Executive Committee Collaborative Research Award Panel of Judges (2007 –2010).  
California Society of Pathologists (1979 – 1985)  
Chicago Pathology Society (1984 – 1986)  
College of American Pathologists (CAP) (1990 – present)  
International Academy of Pathology, (IAP), (United States-Canadian Division) (1985 – present)  
International Society of Urologic Pathology (ISUP) (founding member) (1991 – present)  
Lesch-Nyhan Syndrome Board of Directors and Scientific Advisory Board (1998 – present)  
Maryland Society of Pathologists (1986 – 1991)  
Minnesota Society of Clinical Pathologists (1991 – 1999)  
Zumbro Valley Medical Society (1991 – 1999)  
New York Academy of Sciences (1990 – 2000)  
Virginia Society for Pathologists (2000 – 2006)  
Virginia State Tumor Registry (2000 – 2002)  
Economics Club of New York (2009-2010)

## **EDUCATIONAL ACTIVITIES**

1984 – 1986	Lecturer, Year Two Pathology, University of Chicago School of Medicine.
1986 – 1991	Lecturer, Year Two Pathology, University of Maryland School of Medicine. Pathology Residency Training Program Committee, Department of Pathology, University of Maryland Hospitals and Clinics. Director, School of Medical Technology, Mercy Medical Center and Loyola College.
1993 – 1994	Adjunct Professor of Pathology, University of Ancona, Ancona, Italy.

- 1991 – 1997 Co-Director, Year Two Pathophysiology Course, Mayo Medical School. (Responsible for implementation and execution of a new pathology course in 1992.)
- 1993 – 2002 Founder and Faculty Director, "Pathology of the Prostate," (postgraduate short course), American Society of Clinical Pathologists.
- 1994 – 1998 Founder and Faculty Co-Director, "Premalignant Lesions in Urologic Pathology," (postgraduate short course), US and Canadian Academy of Pathology.
- 1995 – 2000 Faculty Member, American Urologic Association, Urology Board Review Course. Received "Top Teacher" honors each year from the students.
- 1997 – 2001 Founder and Faculty Director, "Pathology of the Bladder," (postgraduate short course) American Society of Clinical Pathologists.
- 2000 – 2001 Faculty Course Director, American Urological Association, Urology Board Review Course. Received "Top Teacher" honors each year from the students.
- 2002 – 2007 Founder and Faculty Director, American and Canadian Urology Board Review Course; sponsored by Bostwick Laboratories
- 2014 Founder and Faculty Co-Director, "Pathology of the Prostate," (postgraduate short course), College of American Pathologists

**INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE MEMBERSHIPS, AND OTHER ACTIVITIES**

Mercy Medical Center, Baltimore, MD  
 Medical Executive Committee 1986 – 1991

Mayo Clinic and Mayo Medical School, Rochester, MN  
 Education Committee, Department of Pathology, 1991 – 1993  
 Research Committee, Department of Pathology, 1993 – 1998  
 Faculty Development Committee, 1991–1994  
 Co-Director, Year Two Pathophysiology Course, 1991 – 1997  
 Mayo Diagnostic Laboratory Committee, 1996 – 1998  
 Mayo Clinic Tissue Committee, 1996 – 1999

International Society of Urologic Pathology  
 Co-founder and Treasurer, 1991–1995  
 Secretary, 1997 – 1999  
 President-Elect, 1999 – 2001  
 President, 2001 – 2003

Journal of Urologic Pathology  
Founder and Editor-in-Chief, 1993 – 1997  
Editor Emeritus, 1997 – 2000

American Cancer Society  
Prostate Cancer Task Force, 1990 – 1998  
Chairman, Prostate Cancer Task Force, 1998  
Planning Committee, First International Consultation on  
Prostate Cancer, 1990 – 1991

College of American Pathologists  
State Commissioner of Maryland, Laboratory  
Accreditation Program, 1989 – 1991  
Laboratory Inspector, 1986 – present  
Member, Cancer Committee, 1996 – 2000

Children's Research Foundation for Lesch-Nyhan Syndrome  
Secretary and Founding Member, 1996 – present

Erasmus University, Rotterdam (The Netherlands)  
Consultant, University Tissue Bank Resources, Sept 2014 (pending)

## **JOURNAL EDITORIAL BOARDS**

### **Previous (terms expired)**

American Journal of Surgical Pathology  
Cancer (Associate Editor 2000)  
Human Pathology  
Prostate  
Prostate Cancer and Prostatic Diseases  
World Journal of Urology

### **Current**

American Journal of Clinical Pathology  
Annals of Diagnostic Pathology  
Modern Pathology  
Pathology Case Reviews  
Urologic Oncology

## **EXTERNAL ADVISORY BOARDS**

1995–1997

Emory University, Atlanta, GA; Prostate Cancer Project (Dr. S. Graham, PI)

1996–1998

University of Virginia, Charlottesville, VA; Prostate Cancer Project (Dr. L. Chung, PI)

2000–2001

White Plains Cancer Center, White Plains, NY

## **CLINICAL PRACTICE AND INTERESTS**

Diagnostic surgical pathology, with special emphasis on urologic pathology  
Genetic testing, with emphasis on next-generation sequencing

## **OTHER**

21<sup>st</sup> Century Award for Achievement, International Biographical Centre, Cambridge, England, 2006

America's Top Doctors, Castle Connolly Guide, 2000 – present

Dictionary of International Biography, 33<sup>rd</sup> Ed, 2006

The Top 25 of the Past 25, The Venture Forum 25<sup>th</sup> Anniversary Celebration Award, 2010.

Ernest & Young Entrepreneur of the Year Award, Washington, D.C., HealthCare Division, 2009

## **RESEARCH INTERESTS**

- Prognostic Factors in Prostate Cancer
- Diagnostic Urologic Pathology
- Precursors of Prostate Cancer
- Pathology of the Prostate, Kidney, Bladder, Testis
- Gastrointestinal Pathology
- Genetic Testing
- Gynecologic Pathology

## **RESEARCH GRANTS AWARDED**

Title: Precursors of Prostate Cancer

Principal Investigator: ***D.G. Bostwick***

Source: American Cancer Society, Illinois Division

Period: 1985 – 1986

Title: SPORE in Prostate Cancer; Project 6: The Role of Prostatic Intraepithelial Neoplasia (PIN)

Principal Investigator: D.J. Tindall

Source: NIH-CA-58225

Period: September 1992 through August 1995

Title: Molecular Biology of Prostatic Intraepithelial Neoplasia (PIN) and Adenocarcinoma

Principal Investigator: **D.G. Bostwick**

Source: Mayo Clinic Intramural Grant-CR20

Period: January 1, 1995 through December 31, 1995

Title: Amphiregulin in Prostate Cancer

Principal Investigator: N.J. Maihle

Source: Pardee Foundation

Period: January 1, 1996 through December 31, 1996

Title: Chemoprevention of Prostate Cancer in Men with Prostatic Intraepithelial Neoplasia (PIN)

Principal Investigator: **D.G. Bostwick** (S. Alberts as of June 1, 1999)

Source: NIH Master Agreement

Period: September 30, 1996 through September 29, 2001

Title: Phase I Studies of New Chemopreventive Agents

Principal Investigator: J.J. Lipsky

Source: NIH-NCI-N01-CN-65008-70

Period: September 1, 1996 through September 30, 1998

Title: Standardization of Her2/Neu Testing Using Cell-Culture Based Controls

Principal Investigator: J. Qian

Source: SBIR/NIH-1R43 CA91521-01

Period: September 2001 through August 2002

Title: Phase IIa Trial: An Efficacy Study to Determine Whether GTX-006 Has Chemoprevention Program Activity Against Prostate Cancer

Principal Investigator: **D.G. Bostwick**

Source: Genotherapeutics

Period: 2001 – 2003

Title: A Randomized, Double Blinded, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer.

Central Pathologist: **D.G. Bostwick**

Source: GlaxoSmithKline

Period: 2003 – 2007

## BIBLIOGRAPHY

### Original Articles

1. Stoner G, Harris C, ***Bostwick DG***, Jones R, Trump BF, Kingbury E, Fineman E, Newkirk C. Isolation and Characterization of Epithelial Cells from Bovine Pancreatic Duct. *In Vitro* 1978 Jul; 14(7):581–590.
2. Katoh Y, Stoner GD, ***Bostwick DG***, Lavappa KS, Myers GA, Fineman E, Valerio M. Morphological, Growth, and Chromosomal Changes in Bovine Pancreatic Duct Epithelial Cells Exposed to N-Methyl-N-Nitrosoguanidine. *In Vitro* 1980 Sep; 16(9):791–796.
3. ***Bostwick DG***. Amphetamine Induced Cerebral Vasculitis. *Hum. Pathol.* 1981 Nov; 12(11):1031–1033.
4. ***Bostwick DG***, Bensch DG, Burke JF, Billingham MG, Miller DC, Smith J, and Keren DG. Whipple's Disease Presenting as Aortic Insufficiency. *N. Engl. J. Med.* 1981 Oct; 22;305(17):995–998.
5. ***Bostwick DG***, Egbert BM and Fajardo LF. Radiation Injury of the Normal and Neoplastic Prostate. *Am. J. Surg. Pathol.* 1982 Sep; 6(6):541–551.
6. Roth KA, Evans CJ, Weber E, Barchas D, ***Bostwick DG***, and Bensch KG. Gastrin Releasing Peptide-Related Peptides in a Human Malignant Lung Carcinoid. *Cancer Res.* 1983 Nov; 43(11):5411–5415.
7. ***Bostwick DG*** and Fajardo LF. Radiation Injury of the Neoplastic Prostate. *Am. Soc. of Clin. Pathol. (ASCP)* 1983; AP 83–85; AP–113.
8. Wilson DM, Ceda GP, ***Bostwick DG***, Webber RJ, Minkoff JR, Pont A, Hintz RL, Bensch KG, Kraemer FB, Rosenfeld RG, et al. Acromegaly and Zollinger-Ellison Syndrome Secondary to an Islet Cell Tumor: Characterization and Quantification of Plasma and Tumor Human Growth Hormone-Releasing Factor. *J. Clin. Endoc. Metab.* 1984 Nov; 59(5):1002–5.
9. ***Bostwick DG***, Quan R, Hoffman AR, Webber RJ, Chang KJ, and Bensch KG. Growth-Hormone-Releasing Factor Immunoreactivity in Human Endocrine Tumors. *Am. J. Pathol.* 1984 Nov; 117(2):167–170.
10. McNeal JE, ***Bostwick DG***. Anatomy of the Prostatic Urethra. *JAMA* 1984 Feb; 17;251(7):890–1.
11. ***Bostwick DG***, Bensch KG, Roth KA, Evans CJ, and Barchas JD. Gastrin Releasing Peptide, A Mammalian Analog of Bombesin, is Present in Human Neuroendocrine Lung Tumors. *Am. J. Pathol.* 1984 Nov; 117(2):195–200.
12. ***Bostwick DG***, Roth KA, Barchas JD, and Bensch KG. Gastrin-Releasing Peptide Immunoreactivity in Intestinal Carcinoids. *Am. J. Clin. Pathol.* 1984 Oct; 82(4):428–431.
13. ***Bostwick DG***, Lo R, and Stamey TA. Papillary Adenocarcinoma of the Urethra. Case Report and Review of the Literature. *Cancer* 1984 Dec 1;54(11):2556–2563.
14. ***Bostwick DG***, Kindrachuk RA, and Rouse R. Prostatic Adenocarcinoma with Endometrioid Features: Clinical Pathology and Ultrastructural Features. *Am. J. Surg. Pathol.* 1985 Aug; 9(8):595–609.



15. ***Bostwick DG*** and Mann RB. Malignant Lymphoma Involving the Prostate: A Study of 13 Cases. Cancer 1985 Dec; 15;56(12):2932–8.
16. Brawer MK, Peehl DM, Stamey TA, and ***Bostwick DG***. Keratin Immunoreactivity in Normal and Neoplastic Prostate. Cancer Res. 1985 Aug; 45(8):3663–3667.
17. Tazelaar HD, ***Bostwick DG***, Ballon SC, Hendrickson MR, and Kempson RL. Conservative Treatment of Borderline Ovarian Tumors. Obstet. Gynecol. 1985 Sep; 66(3):417–422.
18. Weber S, Zuckerman JE, ***Bostwick DG***, Bensch KG, Sikic BI, and Raffin TA. Gastrin Releasing Peptide is a Selective Mitogen for Small Cell Carcinoma In Vitro. J. Clin. Invest. 1985 Jan; 75(1):306–9.
19. ***Bostwick DG*** and Bensch KG. Gastrin Releasing Peptide in Human Neuroendocrine Tumors. J. Pathol. 1985 Dec; 147(4):237–244.
20. ***Bostwick DG***, Tazelaar HD, Ballon SC, Hendrickson MR and Kempson RL. Ovarian Tumors of Low Malignant Potential: A Clinical and Pathologic Study of 109 Cases. Cancer 1986; 58:2052–2065.
21. Panje WR, Moran WJ, ***Bostwick DG***, and Kitt VV. Angiosarcoma of the Head and Neck: Review of 11 Cases. Laryngoscope 1986 Dec; 96(12):1381–1384.
22. Brawer MK, ***Bostwick DG***, Peehl DM, and Stamey TA. Keratin Protein in Human Prostatic Tissue and Cell Culture. Ann. N.Y. Acad. Sci. 1986; 455:729–731.
23. Hallahan DE, Vogelzang NJ, Borow KM, ***Bostwick DG***, and Simon MA. Cardiac Metastases from Soft Tissue Sarcomas. J. Clinic. Oncol. 1986 Nov; 4(11):1662–1669.
24. ***Bostwick DG***, Tazelaar HD, Ballon SC, Hendrickson MR, Kempson RL. Ovarian Epithelial Tumors of Borderline Malignancy. A Clinical and Pathologic Study of 109 Cases. Cancer. 1986 Nov; 1;58(9):2052-65.
25. Lynes WL, ***Bostwick DG***, Freiha FS, and Stamey TA. Parenchymal Brain Metastases from Adenocarcinoma of Prostate. Urology 1986 Oct; 28(4):280–287.
26. McNeal JE and ***Bostwick DG***. Intraductal Dysplasia: A Premalignant Lesion of the Prostate. Hum. Path. 1986 Jan; 17(1):64–71.
27. McNeal JE, ***Bostwick DG***, Kindrachuk RA, Redwine EA, Freiha FA and Stamey TA. Patterns of Progression in Prostate Cancer. Lancet 1986 Jan; 11; 1(8472):60–63.
28. ***Bostwick DG*** and Brawer MK. Prostatic Intraepithelial Neoplasia and Early Invasion in Prostate Cancer. Cancer 1987 Feb; 15;59(4):788–94.
29. ***Bostwick DG***, Null WE, Holmes D, Weber E, Barchas JD, and Bensch KG. Expression of Opioid Peptides in Human Tumors. N. Engl. J. Med. 1987 Dec; 3;317(23):1439–1443.
30. Baron B, Bitter M, Joseph M, and ***Bostwick DG***. Gastric Adenocarcinoma after Gastric Lymphoma. Cancer 1987 Oct; 15;60(8):1876–1882.
31. Michelassi F, Leuthner S, Lubienski M, ***Bostwick DG***, Rodgers J, Handcock M, and Block GE. Levels of Ras Oncogene Protein Product Parallel Malignant Potential of Different Human Colonic Benign Conditions. Arch. Surg. 1987; 122:1414–1416.

32. Moran WJ, Dobleman TJ, and ***Bostwick DG***. Epithelioid Hamangi-  
endothelioma (Histiocytoid Hemangioma) of the Palate. Laryngoscope 1987  
Nov; 97(11):1299–1302.
33. Chak LY, Cox RS, ***Bostwick DG***, and Hoppe RT. Solitary Plasmacytoma of  
Bone: Treatment, Progression, and Survival. J. Clin. Oncol. 1987 Nov;  
5(11):1811–1815.
34. Michelassi F, Dieterich M, Montag AG, ***Bostwick DG***, Cliniton SK, Visek WJ,  
and Block GE. Increased Levels of Ras Oncogene Protein Product in  
Carcinogen-Induced Rat Colorectal Adenocarcinomas. Surg. For. 1987;  
38:400–402.
35. ***Bostwick DG***. Pre-malignant Lesions of the Prostate. Semin. Diag. Pathol.  
1988 Aug; 5(3):240-53.
36. Carlei F, Lygidakis NJ, Speranza V, Brummelkamp WH, McGurrin JF, and  
Lezoche E, Pietroletti R, and ***Bostwick DG***. Neuroendocrine Innervations of  
the Hepatic Vessels in the Rat and in Man. J. Surg. Res. 1988 Nov; 45(5):417–  
426.
37. Clinton SK, ***Bostwick DG***, Olson LM, Mangian HJ, and Visek WJ. Ammonia  
and Cholic Acid as Promoters of N-Methyl-N-Nitrosoguanidine (MNNG)  
Induced Colon Carcinogenesis in Rats. Can. Res. 1988;48:3035–3039.
38. Jockle GA, Lopez I, and ***Bostwick DG***. Campylobacter Pyloridis Associated  
Gastritis. Am. Soc. of Clin. Path. (ASCP) Tech. Sample Series 1988; HT–6.
39. Tacker JR, Basset JB, Anderson RU, and ***Bostwick DG***. Treatment of  
Experimental Bladder Cancer with Hyperthermia and Transitional Phase  
Liposomes Containing Methotrexate. J. Urol. 1988; 139:634–636.
40. ***Bostwick DG***. Premalignant and Other Unusual Lesions of the Prostate. Am.  
Soc. of Clin. Pathol. (ASCP) Check Sample Series, 1988; TD88–3(TD8–89).
41. ***Bostwick DG***. Premalignant Lesions of the Prostate. Sem. Diag. Pathol. 1988  
Aug; 5(3):240–253.
42. Clinton SK, ***Bostwick DG***, Olson LM, Mangian HJ, Visek WJ. Effects of  
Ammonium Acetate and Sodium Cholate on N-methyl-N-nitro-N-  
nitrosoguanidine-induced Colon Carcinogenesis of Rats. Cancer Res. 1988 Jun;  
1;48(11):3035–9.
43. Tetu B, Ro JY, Ayala AG, Srigley JR, Begin LR, and ***Bostwick DG***. Atypical  
Spindle Cell Lesions of the Prostate. Sem. Diag. Pathol. 1988 Aug; 5(3):284–  
93.
44. ***Bostwick DG***. The Pathology of Early Prostate Cancer. CA Can. J. for Clin.  
1989 Nov–Dec; 39(6):376–393.
45. ***Bostwick DG***. Prostatic Intraepithelial Neoplasia and Early Invasion in  
Prostatic Carcinoma. Urology 1989; 34(6):16–22.
46. Hirsch BZ, Whittington PFR, Kirschner BS, Black DD, ***Bostwick DG***, and  
Yousefzadek DK. Isolated Granulomatous Gastritis in an Adolescent. Dig. Dis.  
Sci. 1989 Feb; 34(2):292–296.
47. Freije SA, Mostofi RS, and ***Bostwick DG***. Alterations in Glycoconjugate  
Expression Following Malignant Transformation of Human Oropharyngeal  
Squamous Mucosa. Laryngoscope 1989 Feb; 99(2):197–203.

48. Berkelhammer CH, Baker AL, Block GE, ***Bostwick DB***, and Michelassi F. Humoral Hypercalcemia Complicating Adenosquamous Carcinoma of the Proximal Colon. Dig. Dis. Sci. 1989 Jan; 34(1):142–147.
49. Dieterich M, Clinton SK, Olson LM, Erroi F, ***Bostwick DG***, Montag AG, and Visek WJ. Expression of Ras Oncogene in N-Methyl-N-Nitro-Soguanidine-Induced Rat Colon Tumors. Res. Surg. 1989; 1:113–117.
50. ***Bostwick DG***. Prostatic Intraepithelial Neoplasia (PIN). Urology. 1989 Dec; 34(6 Suppl):16–22.
51. Lashner BA, Turner BC, ***Bostwick DG***, Frank PH, Hanauer SB. Dysplasia and Cancer Complicating Strictures in Ulcerative Colitis. Dig. Dis. Sci. 1990 Mar; 35(3):349–52.
52. Mills SE, ***Bostwick DG***, Murphy WM, Weiss MA. A Symposium on the Surgical Pathology of the Prostate. Pathol. 1990; 25(2):109–58.
53. Weaver MG, Abdul-Karim FW, Srigley J, ***Bostwick DG***, Ro JY, Ayala AG. Paneth Cell-Like Change of the Prostate Gland. A Histological, Immunohistochemical, and Electron Microscopic Study. Am. J. Surg. Pathol. 1992 Jan; 16;(1):62-8.
54. ***Bostwick DG***, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The Association of Benign Prostatic Hyperplasia and Cancer of the Prostate. Cancer 1992 Jul; 1;70(Suppl 1):291–301.
55. ***Bostwick DG***. Prostatic Intraepithelial Neoplasia (PIN): Current Concepts. J. Cell. Biochem. 1992; 16H:10–19.
56. ***Bostwick DG***. Natural History of Early Bladder Cancer. J. Cell Biochem. 1992; 161:31–38.
57. Graham SD Jr, ***Bostwick DG***, Hoisaeter A, Abrahamsson P, Algaba F, di Sant'Agnes A, Mostofi FK, Napalkov P. Report of the Committee on Staging and Pathology. Cancer. 1992 Jul; 1;70(Suppl):359-61.
58. ***Bostwick DG***, Montironi R, Nogle R, Pretlow T, Miller G, Wheeler T, Epstein J, Sakr W. Current and Proposed Biologic Markers in Prostate Cancer. J. Cell Biochem. Suppl. 1992; 16H:65–7.
59. Williams RD, ***Bostwick DG***, Boone CW, Catalona WJ, McKeehan W, Thompson IM. When Is Intervention Warranted? J. Cell. Biochem. Suppl. 1992; 16H:138–9.
60. ***Bostwick DG***, Bose D, Srigley J, Grignon D, Maksem J, van der Kwast T, Humphrey P, Young R. Atypical Adenomatous Hyperplasia (AAH) of the Prostate: Morphologic Criteria for Its Distinction from Well-Differentiated Carcinoma. Hum. Pathol. 1993 Aug; 24;(8):819–832.
61. ***Bostwick DG***, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural Patterns of High Grade Prostatic Intraepithelial Neoplasia. Hum. Pathol. 1993; Mar; 24;(3):298–310.
62. ***Bostwick DG***, Graham SD, Napalkov P, Abrahamsson PA, di Sant'Agnes PA, Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, Denis L, Schroeder F, Murphy GP. Staging of Early Prostate Cancer: A Proposed Tumor Volume-Based Prognostic Index. Urology 1993 May; 41(5):403–411.

63. Durham JR, ***Bostwick DG***, Farrow GM, Ohorodnik JM. Mesoblastic Nephroma of Adulthood. Report of Three Cases. Am. J. Surg. Pathol. 1993 Oct 17; (10):1029–1038.
64. Aran PP, Bissel MG, Whittington PF, ***Bostwick DG***, Adamac T, Baker AL.
65. Diagnosis of Hepatic Allograft Rejection: Role of Liver Biopsy. Clin. Trans. 1993 Oct; 7(5):475–81.
66. Devaraj LT and ***Bostwick DG***. Atypical Basal Cell Hyperplasia and Adenoid Basal Cell Tumor of the Prostate: Immunophenotypic Profile and Proposed Classification of Basal Cell Proliferations. Am. J. Surg. Pathol. 1993 Jul; 17;(7):645–659.
67. Bovenberg SA, van der Zwet CJJ, van der Kwast TH, Marzella L, and ***Bostwick DG***. Prostate Specific Antigen Expression in Prostate Cancer and its Metastases. J. Urol. Pathol. 1993; 1:55–61.
68. Fain JS, Cosnow I, King BF, Zincke H, ***Bostwick DG***. Cystosarcoma Phyllodes of the Seminal Vesicle. Cancer 1993 Mar; 15;71(6):2055–2061.
69. ***Bostwick DG*** and de La Roza G. Intraepithelial Neoplasia: A Call for Standardized Terminology. J. Urologic Pathol. 1993; 1:95–103.
70. Oesterling JE, Suman VJ, ***Bostwick DG***. PSA-Detected (Clinical Stage T1c or B0) Prostate Cancer. Urol. Clin. N. Amer. 1993 Nov; 20;(4):687–693.
71. Jones GW, Smith RA, Batjer JD, ***Bostwick DG***, Corn BW, Guess HA, Hudson MA, Kabalin J, Soloway MS. Workgroup #3: Monitoring Effects of Treatment for Cancer and for Benign Prostatic Hyperplasia. Cancer. 1993 Apr; 15;71(8):2681–3.
72. ***Bostwick DG***, Myers RP, Oesterling JE. The Staging of Prostate Cancer. Sem. in Surg. Oncol. 1994 Jan-Feb; 10(1):60–72.
73. Adalkha H, ***Bostwick DG***. Paneth Cell-like Change in Prostatic Adenocarcinoma Represents Neuroendocrine Differentiation: Report of 30 Cases. Hum. Pathol. 1994 Feb; 25;(2):135–139.
74. ***Bostwick DG***, Al Annouf N, Choi C. Establishment of the Formalin-Free Surgical Pathology Laboratory: Utility of an Alcohol-Based Fixative. Arch. Pathol. Lab Med. 1994 Mar; 118(3):298–302.
75. Sebo TJ, ***Bostwick DG***, Farrow GM, Eble JN. Prostatic Xanthoma: A Mimic of Prostatic Adenocarcinoma. Hum. Pathol. 1994 Apr; 25;(4):386–389.
76. Blackwell KL, ***Bostwick DG***, Zincke H, Myers, RP, Oesterling JE. Combining Prostate Specific Antigen with Cancer and Gland Volume to More Reliably Predict Pathologic Stage: The Influence of PSA-Cancer Density. J. Urol. 1994 Jun; 151(6):1565–1570.
77. Chiang KS, Larson TS, LeRoy AH, Swee R, ***Bostwick DG***. CT of Erdheim-Chester Disease Presenting as Retroperitoneal Xanthogranulomatosis. J. Comp. Asst. Tomog. 1994 May-Jun; 18(3):503–505.
78. ***Bostwick DG***. Gleason Grading of Prostatic Needle Biopsies: Correlation with Grade in 316 Matched Prostatectomies. Am. J. Surg. Pathol. 1994; Aug; 18(8):796–803.
79. Ferguson J, ***Bostwick DG***, Ellison E, Bergstrahl, Zincke H. Decrease of Prostatic Intraepithelial Neoplasia (PIN) Following Androgen Deprivation

- Therapy in Patients with Stage T3 Prostatic Carcinoma Treated by Radical Prostatectomy. J. Urol. 1994 Jul; 44(1):91–95.
80. **Bostwick DG**. Standardization and Quality Control of Surrogate Endpoint Biomarkers Assays for Prostate Cancer. J. Cell. Biochem. 1994; Suppl. 19; 189–190.
  81. **Bostwick DG**. Target Populations and Strategies for Chemoprevention Trials of Prostate Cancer. J. Cell. Biochem. 1994; Suppl. 19; 191–196.
  82. **Bostwick DG**, Qian J. Current and Proposed Biologic Markers in Prostate Cancer: 1994. J. Cell. Biochem. 1994; 19:197–201. Review.
  83. **Bostwick DG**. The Most Promising Surrogate Endpoint Biomarkers for Screening Candidate Chemopreventive Compounds for Prostatic Adenocarcinoma in Short-Term Phase II Clinical Trials. J. Cell. Biochem. 1994; Suppl. 19; 283–289.
  84. **Bostwick DG**. Prostate-Specific Antigen: Current Role in Diagnostic Pathology of Prostate Cancer. Am. J. Clin. Pathol. 1994 Oct; 102(4 Suppl. 1):S31–S37.
  85. **Bostwick DG**. Grading Prostate Cancer. Am. J. Clin. Pathol. 1994 Oct; 102(4 Suppl. 1):S38–S56.
  86. **Bostwick DG**, Dousa MK, Crawford BG, Wollan PC. Neuroendocrine Differentiation in Prostatic Intraepithelial Neoplasia and Adenocarcinoma. Am. J. Surg. Pathol. 1994 Dec; 18(12):1240–1246.
  87. **Bostwick DG**, Vonk JB, Picado A. Pathologic Changes in the Prostate Following Contemporary 18 Gauge Needle Biopsy: No Apparent Risk of Local Cancer Seeding. J. Urol. Pathol. 1994; 2:203–211.
  88. Gierke CL, King BF, **Bostwick DG**, Choyke PL, and Hattery RR. Large-Cell Calcifying Sertoli Cell Tumor of the Testis: Appearance at Sonography. Am. J. Roentg. 1994 Aug; 163(2):373–5.
  89. Bluestein DL, **Bostwick DG**, Bergstralh E, and Oesterling JE. Eliminating the Need for Bilateral Pelvic Lymphadenectomy in Select Patients with Prostate Cancer. J. Urol. 1994 May; 151(5):1315–1320.
  90. Takahashi S, Qian J, Brown JA, Alcaraz A, **Bostwick DG**, Lieber MM, Jenkins RB. Potential Markers of Prostate Cancer Aggressiveness Detected by Fluorescence In Situ Hybridization in Needle Biopsies. Cancer Res. 1994 Jul; 54(13):3574–3579.
  91. **Bostwick DG**. c-erbB-2 Oncogene Expression in Prostatic Intraepithelial Neoplasia: Mounting Evidence for a Precursor Role. J. Natl. Can. Inst. 1994; Aug; 86(15):1108–1110.
  92. **Bostwick DG**, Algaba F, Amin MB, Ayala A, Eble J, Goldstein N, Helpap B, Humphrey P, Grignon D, Jones EC. Consensus Statement on Terminology: Recommendation to Use Atypical Adenomatous Hyperplasia in Place of Adenosis of the Prostate. Human Pathol. 1994 Aug; 25(8):840.
  93. **Bostwick DG**. Precursor of Prostate Cancer. Cancer 1995; 75:1823–1836.
  94. **Bostwick DG**, Larson TR. Transurethral Microwave Thermal Therapy: Pathologic Findings in the Canine Prostate. Prostate 1995 Mar; 26(3):116–122.
  95. Kletscher BA, Qian J, **Bostwick DG**, Andrews PE, Zincke H. Prospective Analysis of Multifocality in Renal Cell Carcinoma: Influence of Histological Pattern, Grade, Number, Size, Volume, and Deoxyribonucleic Acid

- Ploidy. *J. Urol.* 1995 Mar; 153(3 Pt. 2):904–906.
96. ***Bostwick DG***, Qian J. Atypical Adenomatous Hyperplasia of the Prostate: Relationship with Carcinoma in 217 Whole-Mount Radical Prostatectomies. *Am. J. Surg. Pathol.* 1995 May; 19(5):506–518.
  97. ***Bostwick DG***, Wollan P, Adlakha K. Collagenous Micronodules in Prostate Cancer: A Specific but Infrequent Diagnostic Finding. *Arch. Pathol. Lab. Med.* 1995 May; 119(5):444–447.
  98. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang A, ***Bostwick DG***, Liotta LA, and Linehan WM. Allelic Loss on Chromosome 8p12–21 in Micro Dissected Prostatic Intraepithelial Neoplasia. *Can. Res.* 1995 Jul; 55(14):2959–2962.
  99. Cupp MR, ***Bostwick DG***, Myers RP, Oesterling JE. The Volume of Prostate Cancer in the Biopsy Specimen Cannot Reliably Predict the Quantity of Cancer in the Radical Prostatectomy Specimen on an Individual Basis. *J. Urol.* 1995 May; 153(5):1543–1548.
  100. ***Bostwick DG***. Clinical Utility of Prostatic Intraepithelial Neoplasia. *Mayo Clin. Proc.* 1995 Apr; 70(4):395–396.
  101. ***Bostwick DG***. The Pathology of Incidental Carcinoma. *Can. Surv.* 1995; 23:7–18.
  102. ***Bostwick DG***, Leske DA, Qian J, Sinha AA. Prostatic Intraepithelial Neoplasia and Well Differentiated Adenocarcinoma Maintain an Intact Basement Membrane. *Path. Res. Pract.* 1995 Sept; 191(9):850–855.
  103. ***Bostwick DG***, Montironi. Prostatic Intraepithelial Neoplasia and the Origins of Prostatic Carcinoma. *Path. Res. Pract.* 1995 Sept; 191(9):828–32.
  104. Qian J, ***Bostwick DG***. The Extent and Zonal Location of Prostatic Intraepithelial Neoplasia and Atypical Adenomatous Hyperplasia: Relationship with Carcinoma in Radical Prostatectomy Specimens. *Path. Res. Pract.* 1995 Sept; 191(9):860–867.
  105. Ferguson JK, ***Bostwick DG***, Suman V, Zincke H, Oesterling JE. Prostate-Specific Antigen Detected Prostate Cancer: Pathological Characteristics of Ultrasound Visible Versus Ultrasound Invisible Tumors. *Eur. Urol.* 1995; 27(1):8–12.
  106. Qian J, ***Bostwick DG***, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB. Chromosomal Anomalies in Prostatic Intraepithelial Neoplasia and Carcinoma Detected by Fluorescence In Situ Hybridization. *Can. Res.* 1995 Nov; 55(22): 5408–14.
  107. ***Bostwick DG***, Qian J, Frankel K. ***Bostwick DG***, Qian J, Frankel K. The Diagnosis of High Grade Prostatic Intraepithelial Neoplasia on Needle Biopsies. *J. Urol.* 1995 Nov; 154(5):1791–4.
  108. Qian J, Jenkins RB, ***Bostwick DG***. Chromosomal Anomalies in Atypical Adenomatous Hyperplasia and Carcinoma of the Prostate Detected by Fluorescence In Situ Hybridization. *Urology* 1995 Dec; 46(6):837–842.
  109. Goldstein N, Qian J, ***Bostwick DG***. Mucin Expression in Atypical Adenomatous Hyperplasia of the Prostate. *Hum. Pathol.* 1995 Aug; 26(8):887–891.

110. ***Bostwick DG***, Frankel K, Qian J. The Incidence of High Grade Prostatic Intraepithelial Neoplasia and Cancer in Contemporary Needle Biopsies. Hum. Pathol. 1995; 154:1791–1794.
111. Dundore PA, Nascimento AG, Cheville JC, ***Bostwick DG***. Carcinosarcoma of the Prostate: Report of 21 Cases. Cancer 1995 Sept; 15;76(6):1035–1042.
112. Davidson D, ***Bostwick DG***, Qian J, Wollan P, Oesterling JE, Rudders RA, Siroky M, Stilmant M. Prostatic Intraepithelial Neoplasia is a Risk Factor for Adenocarcinoma: Predictive Accuracy in Needle Biopsies. J. Urol. 1995 Oct; 154(4):1295–1299.
113. Cheville JC, ***Bostwick DG***. Postatrophic Hyperplasia of the Prostate. Am. J. Surg. Pathol. 1995; 1068–76.
114. MacLennan GT, ***Bostwick DG***. Microvessel Density in Renal Cell Carcinoma: Lack of Prognostic Significance. Urology, 1995 Jul; 46(1):27–30.
115. Cheville JC, ***Bostwick DG***. Postatrophic Hyperplasia of the Prostate. A Histologic Mimic of Prostatic Adenocarcinoma. Am. J. Surg. Pathol. 1995 Sept; 19(9):1068–76.
116. Salomao DR, Graham SD, ***Bostwick DG***. Microvascular Invasion in Prostate Cancer Correlates with Pathologic Stage. Arch. Pathol. Lab. Med. 1995 Nov; 119(11):1050–1054.
117. Ferreiro JA, Myers JL, ***Bostwick DG***. Accuracy of Frozen Section in Surgical Pathology: Review of a 1-Year Experience with 24,880 Cases at Mayo Clinic Rochester. Mayo Clin. Proc. 1995 Dec; 70(12):1137–1141.
118. Ferreiro JA, Gisvold JJ, ***Bostwick DG***. Accuracy of Frozen-Section Diagnosis of Mammographically Directed Breast Biopsies: Results of 1,490 Consecutive Cases. Am. J. Surg. Pathol. 1995 Nov; 19(11):1267–1271.
119. Cheville JC, Dundore PA, Nascimento AG, Meneses M, Kleer E, Farrow GM, and ***Bostwick DG***. Leiomyosarcoma of the Prostate: Report of 23 Cases. Cancer 1995 Oct; 15;76(8):1422–1427.
120. Helpap BG, ***Bostwick DG***, Montironi R. The Significance of Atypical Adenomatous Hyperplasia and Prostatic Intraepithelial Neoplasia for the Development of Prostate Carcinoma: An Update. Virchows Arch. 1995; 426(5):425–434.
121. Takahashi S, Shan AL, Ritland SR, Delacey KA, ***Bostwick DG***, Lieber MM, Thibodeau SN, and Jenkins RB. Frequent Loss of Heterozygosity at 7q31.1 in Primary Prostate Cancer is Associated with Tumor Aggressiveness and Progression. Can. Res. 1995 Sept; 15;55(18):4114–4119.
122. Goldstein NS, Begin LR, Grody WW, Novak JM, Qian J, ***Bostwick DG***. Minimal or no Cancer in Radical Prostatectomy Specimens: Report of 13 Cases of the “Vanishing Cancer Phenomenon.” Am. J. Surg. Pathol. 1995 Sept; 19(9):1002–1009.
123. Monda JM, Myers RP, ***Bostwick DG***, Oesterling JE. The Correlation Between Serum Prostate-Specific Antigen and Prostate Cancer is not Influenced by the Serum Testosterone Concentration. Urology. 1995 Jul; 46(1):62–4.
124. Schneider BG, Pulitzer DR, Brown RD, Prihoda TJ, ***Bostwick DG***, Saldivar V, Rodriguez-Martinez HA, Gutierrez-Diaz ME, and O’Connell P. Allelic Imbalance in Gastric Cancer: An affected Site on Chromosome Arm 3p. Genes, Chrom. & Can. 1995 Aug; 13(4):263–71.

125. Monda JM, Myers RP, ***Bostwick DG***, Oesterling JE. The Correlation between Serum Prostate-Specific Antigen and Prostate Cancer is not Influenced by the Serum Testosterone Concentration. *Urology* 1995; 46:62–4.
126. Dugan JA, ***Bostwick DG***, Myers RP, Qian J, Bergstralh EJ, Dundore P, Myers RP, Oesterling JE. The Definition and Preoperative Prediction of Clinically Insignificant Prostate Cancer. *JAMA* 1996 Jan; 275(4):288–94.
127. Pisansky TM, Zincke H, Suman VJ, ***Bostwick DG***, Earle JD, and Oesterling JE. Correlation of Pretherapy Prostate Cancer Characteristics with Histologic Findings from Pelvic Lymphadenectomy Specimens. *Int. J. Rad. Oncol. Biol. Phys.* 1996 Jan; 1;34:33–39.
128. ***Bostwick DG***, Qian J, Bergstralh E, Dundore P, Dugan J, Myers RP, Oesterling JE. Prediction of Capsular Perforation and Seminal Vesicle Invasion in Prostate Cancer. *J. Urol.* 1996; 155:1361–1367.
129. Gould VE, Doljanskaia V, Gooch G, ***Bostwick DG***. Immunolocalization of Glycoprotein A-80 in Prostatic Carcinoma and Prostatic Intraepithelial Neoplasia. *Hum. Pathol.* 1996 Jun; 27(6):547–552.
130. Alexander EE, Qian J, PC, Wollan PC, Myers RP, ***Bostwick DG***. Prostatic Intraepithelial Neoplasia Does Not Appear to Raise Serum Prostate-Specific Antigen Concentration. *Urology* 1996 May; 47(5):693–698.
131. Vocke CD, Pozzatti RO, ***Bostwick DG***, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. Analysis of 99 Microdissected Prostate Carcinomas Reveals a High Frequency of Allelic Loss on Chromosome 8p12–21. *Cancer Res.* 1996 May 15; 56(10):2411–2416.
132. Graham SD Jr, Napalkov P, Watts L, Salomao D, ***Bostwick DG***. Microvascular Invasion of the Seminal Vesicles in Adenocarcinoma of the Prostate. *Prostate* 1996 Jun; 28(6):359–363.
133. Brown JA, Takahashi S, Alcaraz A, Borell TJ, Anderl KL, Qian J, Persons DL, ***Bostwick DG***, Lieber MM, Jenkins RB. Fluorescence In Situ Hybridization Analysis of Renal Oncocytoma Reveals Frequent Loss of Chromosomes Y and 1. *J. Urol.* 1996 Jul; 156(1):31–35.
134. ***Bostwick DG***, Pacelli A, Lopez-Beltran A. Molecular Biology of Prostatic Intra-epithelial Neoplasia. *Prostate* 1996 Aug; 29(2):117–134.
135. Ellison E, Chuang SS, Zincke H, Ferguson, ***Bostwick DG***. Prostate Adenocarcinoma after Androgen Deprivation Therapy: A Comparative Study of Morphology, Morphometry, Immunohistochemistry, and DNA Ploidy. *Pathology Case Reviews* 1996; 1:74–83.
136. Amin MB, ***Bostwick DG***. Pigment in Prostatic Epithelium and Adenocarcinoma: A Potential Source of Diagnostic Confusion with Seminal Vesicular Epithelium. *Mod. Pathol.* 1996 Jul; 9(7):791–795.
137. Chen W, Weghorst CH, Sabopurin CLK, Wang Y, ***Bostwick DG***, and Stoner D. Absence of p16/MTS1 Gene Mutations in Human Prostate Cancer. *Carcinogenesis* 1996 Dec; 17(12):2603–2607.
138. ***Bostwick DG***, Aquilina JW. Prostatic Intraepithelial Neoplasia (PIN) and Other Prostatic Lesions as Risk Factors and Surrogate Endpoints for Cancer Chemoprevention Trials. *J. Cell Biochem. Suppl.* 1996; 25:156–164.



139. Qian J, Jenkins RB, ***Bostwick DG***. Potential Markers of Aggressiveness in Prostatic Intraepithelial Neoplasia Detected by Fluorescence in Situ Hybridization. Euro. Urol. 1996; 30(2):177–184.
140. Larson TR, ***Bostwick DG***, Corica A. Temperature-Related Histopathologic Changes Following Microwave Thermoblation of Obstructive Tissue in Patients with Benign Prostatic Hyperplasia. Urology 1996 Apr; 47(4):463–469.
141. Clinton SK, Emenhiser C, Schwartz SJ, ***Bostwick DG***, Williams AW, Moore BJ, Erdman JW, Jr. *Cis-trans* Lycopene Isomers, Carotenoids, and Retinol in the Human Prostate. Can. Epid. Bio. Prev. 1996 Oct; 5(10):823–833.
142. Qian J, ***Bostwick DG***, Takahashi S, Borell TJ, Brown JA, Lieber MM, Jenkins RB. Comparison of Fluorescence In Situ Hybridization Analysis of Isolated Nuclei and Routine Histological Sections from Paraffin-Embedded Prostatic Adenocarcinoma Specimens. Am. J. Pathol. 1996 Oct; 149(4):1193–1199.
143. Kuntzman TS, Malek RS, Barrett DM, ***Bostwick DG***. Potassium-Titanyl-Phosphate Laser Vaporization of the Prostate: A Comparative Functional and Pathologic Study in Canines. Urology 1996 Oct; 48(4):575–583.
144. ***Bostwick DG***, Guthman DA, Letendre L, Banks PM, Texter JH Jr, Lieber MM. Polymorphous Reticulosis (Idiopathic Midline Destructive Disease) of the Penis, Scrotum, and Perineum. J. Urol. Pathol. 1996; 5:57–63.
145. ***Bostwick DG***. Progression of Prostatic Intraepithelial Neoplasia to Early Invasive Adenocarcinoma. Euro. Urol. 1996; 30(2):145–152.
146. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, ***Bostwick DG***, Thibodeau SN. Allelic Imbalance and Microsatellite Instability in Prostatic Adenocarcinoma. Can. Res. 1996 Oct; 1;56(19):4475–4482.
147. Pisansky TM, ML, Suman VJ, ***Bostwick DG***, Earle JD, Zincke H. Correlation of Pre-therapy Prostate Cancer Characteristics with Seminal Vesicle Invasion in Radical Prostatectomy Specimens. Int. J. Rad. Oncol. Biol. Phys. 1996 Oct; 1;6(3):585–591.
148. Young RH, ***Bostwick DG***. Florid Cystitis Glandularis of Intestinal Type with Mucin Expression: A Mimic of Adenocarcinoma. Am. J. Surg. Pathol. 1996 Dec; 20(12):1462–1468.
149. ***Bostwick DG***, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ. Optimized Microvessel Density Analysis Improves Prediction of Cancer Stage from Prostate Needle Biopsies. Urology 1996 Jul; 48(1):47–57.
150. Harmon WJ, Barrett DM, Qian J, Lauvetz RW, ***Bostwick DG***, Gokcen M. Transurethral Enzymatic Ablation of the Prostate (TEAP): Canine Model. Urology 1996 Aug; 48(2):47–57.
151. Burke HB, Goodman PH, Rosen DB, Henson DE, Weinstein JN, Harrell FE, Jr., Marks JR, Winchester DP, ***Bostwick DG***. Artificial Neural Networks Improve the Accuracy of Cancer Survival Prediction. Cancer 1996; 79:857–62.
152. ***Bostwick DG***, Aquilina JW. Prostatic Intraepithelial Neoplasia (PIN) and Other Prostatic Lesions as Risk Factors and Surrogate Endpoints for Cancer Chemoprevention Trials. J. Cell Biochem. Suppl. 1996; 25:156–64.

153. Allam CK, ***Bostwick DG***, Hayes JA, Upton MP, Wade GG, Domanowski GF, Klein MA, Boling EA, Stilmant MM. Interobserver Variability in the Diagnosis of High-Grade Prostatic Intraepithelial Neoplasia and Adenocarcinoma. Mod. Pathol. 1996 Jul; 9(7):742–51.
154. Harmon WJ, Barrett DM, Qian J, Lauvetz RW, ***Bostwick DG***, Gocken M. Transurethral Enzymatic Ablation of the Prostate: Canine Model. Urology 1996; 48:229–33.
155. Montironi R, ***Bostwick DG***, Bonkhoff H, Cockett AT, Helpap B, Troncoso P, Waters D. Origins of Prostate Cancer. Cancer 1996 Jul; 15;78(2):362–5.
156. ***Bostwick DG***. Prospective Origins of Prostate Carcinoma. Prostatic Intraepithelial Neoplasia and Atypical Adenomatous Hyperplasia. Cancer 1996 Jul; 15;78(2):330–6. Review.
157. Amin MB, Grignon D, ***Bostwick DG***, Reuter V, Troncoso P, Ayala AG. Recommendations for the Reporting of Resected Prostate Carcinomas. Association of Directors of Anatomic and Surgical Pathology. Am. J. Clin. Pathol. 1996; 105:667–70.
158. Lerner SE, Blute ML, Bergstralh EJ, ***Bostwick DG***, Eickholt JT, Zincke H. Analysis of Risk Factors for Progression in Patients with Pathologically Confirmed Prostate Cancers after Radical Retropubic Prostatectomy. J. Urol. 1996 Jul; 156(1):137–43.
159. ***Bostwick DG***, Qian J, Bergstralh E, Dundore P, Dugan J, Myers RP, Oesterling JE. Prediction of Capsular Perforation and Seminal Vesicle Invasion in Prostate Cancer. J. Urol. 1996 Apr; 155(4):1361–7.
160. Kletscher BA, Qian J, ***Bostwick DG***, Blute ML, Zincke H. Prospective Analysis of the Incidence of Ipsilateral Adrenal Metastasis in Localized Renal Cell Carcinoma. J. Urol. 1996 Jun; 155(6):1844–6.
161. Fudge K, ***Bostwick DG***, Stearns ME. Platelet-derived Growth Factor A and B Chains and the Alpha and Beta Receptors in Prostatic Intraepithelial Neoplasia. Prostate. 1996 Nov; 29(5):282–86.
162. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, ***Bostwick DG***. A Multiple Prognostic Index Predictive of Disease Outcome after Irradiation for Clinically Localized Prostate Carcinoma. Cancer. 1997 Jan; 15;79(2):337–44.
163. ***Bostwick DG***. Staging Prostate Cancer, 1997: Current Methods and Limitations. Eur. Urol. 1997; 32 Suppl. 3:2–14. Review.
164. Montironi R, Alexander E, ***Bostwick DG***. Prostate Pathology Case Study Seminar. Virchows Arch. 1997 Jan; 430(1):83–94.
165. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, ***Bostwick DG***. Prostatic Intraepithelial Neoplasia in Dogs with Spontaneous Prostate Cancer. Prostate. 1997 Feb; 1;30(2):92–97.
166. Qian J, Wollan P, ***Bostwick DG***. The Extent and Multicentricity of High-Grade Prostatic Intraepithelial Neoplasia in Clinically Localized Prostatic Adenocarcinoma. Hum. Pathol. 1997 Feb; 28(2):143–48.
167. Harlan JW, Petty PM, ***Bostwick DG***. Prostate Cancer Masquerading as a Zygomatic Posttraumatic Mass. Mayo Clin. Proc. 1997 Mar; 72(3):248–50.

168. Aquilina JW, Lipsky JJ, ***Bostwick DG***. Androgen Deprivation as a Strategy for Prostate Cancer Chemoprevention. J. Natl. Can. Inst. 1997 May; 21;89(10):689–696.
169. Egan AJM, Lopez-Beltran A, ***Bostwick DG***. Prostatic Adenocarcinoma with Atrophic Features: Malignancy Mimicking a Benign Process. Am. J. Surg. Pathol. 1997 Aug; 21(8):931–935.
170. Pacelli A, ***Bostwick DG***. The Clinical Significance of High-Grade Prostatic Intraepithelial Neoplasia in Transurethral Resection Specimens. Urology 1997; 50:355–359.
171. Chevillet JC, Clark JR, Neitzel GF, Reznicek M, ***Bostwick DG***. The Focus of Atypical Glands Suspicious for Malignancy in Prostate Needle Biopsy Specimens: Incidence, Histologic Features, and Clinical Follow-up of Cases Diagnosed in a Community Practice. Am. J. Clin. Pathol. 1997 Dec; 108:633–640.
172. MacLennan GT, Farrow GM, ***Bostwick DG***. The Immunophenotype of Renal Cell Carcinoma: Comparative Profiles of the Main Histologic Types Based on Study of 60 Cases. J. Urol. Pathol. 1997; 6:195–204.
173. Schleicher RL, Hunter SH, Bandea CI, Zhang CI, Zheng M, Tan W, Fallon MT, ***Bostwick DG***, Varma VA. Neurofilament Heavy Chain-like mRNA and Protein are Present in Benign Prostate and Downregulated in Prostatic Carcinoma. Can. Res. 1997 Aug; 15;57(16):3532–3536.
174. MacLennan GT, Farrow GM, de Matteis A, ***Bostwick DG***. Collecting Duct Carcinoma of the Kidney: Critical Analysis of Factors Influencing Prognosis with Emphasis on Well Differentiated Carcinoma. Am. J. Surg. Pathol. 1997; 6:195–204.
175. Kuntzman, R., Malek R., ***Bostwick DG***. High Power (60 Watt) Potassium-Titanyl-Phosphate (KP/532) Laser Vaporization Prostatectomy: Observations in Living Canines and in Human and Canine Cadavers. Urology 1997 May; 49(5):703–708.
176. Iczkowski KA, Kiviat J, Chevillet JC, ***Bostwick DG***. Multifocal Capillary Micro-angioma of the Testis. J. Urol. Pathol. 1997; 7:113–120.
177. Jenkins RB, Qian J, Lieber MM, ***Bostwick DG***. Detection of c-myc Oncogene Amplification and Chromosomal Anomalies in Metastatic Prostatic Carcinoma by Fluorescence In Situ Hybridization. Can. Res. 1997 Feb; 1;57(3):524–31.
178. Waters DJ, ***Bostwick DG***. Prostatic Intraepithelial Neoplasia Occurs Spontaneously in the Canine Prostate. J. Urol. 1997 Feb; 257(2):713–16.
179. Qian J, Jenkins RB, ***Bostwick DG***. Detection of Chromosomal Anomalies C-myc Gene Amplification in the Cribriform Pattern of Prostatic Intraepithelial Neoplasia and Carcinoma by Fluorescence In Situ Hybridization. Mod. Pathol. 1997 Nov; 10:1113–1119.
180. ***Bostwick DG***, Iczkowski KA. Minimal Criteria for the Diagnosis of Prostate Cancer on Needle Biopsy. Ann. of Diag. Pathol. 1997 Dec; 1;2:104–129.
181. ***Bostwick DG***, Aquilina JW. Finasteride Shows Modest Pathologic Changes in Prostate Cancer. J. Urol. Pathol. 1997; 6:83–84.
182. Kerley SV, Corica FA, Qian J, Myers RP, ***Bostwick DG***. Peripheral Zone Involvement by Prostatic Hyperplasia. J. Urol. Pathol. 1997; 6:87–94.

183. Gould VE, Doljanskaia V, Gooch GT, ***Bostwick DG***. Stability of the Glycoprotein A-80 in Prostatic Carcinoma Subsequent to Androgen Deprivation Therapy. Am. J. Surg. Path. 1997 Mar; 21(3):319–26.
184. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, ***Bostwick DG***. Human Glandular Kallikrein 2 (hK2) Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Novel Prostate Cancer Marker. Urology. 1997 Jun; 49(6):857–62.
185. Kempton CL, Kurtin PJ, Inwards DJ, Wollan P, ***Bostwick DG***. Malignant Lymphoma of the Bladder: Evidence from 36 Cases that Low-Grade Lymphoma of the MALT-type is the Most Common Primary Bladder Lymphoma. Am. J. Surg. Pathol. 1997 Nov; 21(11):1324–33.
186. Burke HB, Goodman PH, Rosen, DB, Henson DE, Weinstein JN, Harrell FE, Jr, Marks JR, Winchester DP, ***Bostwick DG***. Artificial Neural Networks Improve the Accuracy of Cancer Survival Prediction. Cancer 1997 Feb; 15;79(4):857–62.
187. ***Bostwick DG***. Evaluating Prostate Needle Biopsy: Therapeutic and Prognostic Importance. CA: A Cancer J. for Clinicians 1997 Sept–Oct; 47(5):297–319.
188. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, ***Bostwick DG***, Darson M, Delahunt B, Iczkowski K. Classification of Renal Cell Carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997 Sept; 1;80(5):987–9.
189. Corica FA, Husmann DA, Churchill BM, Young RH, Pacelli A, Lopez-Beltran A, ***Bostwick DG***. Intestinal Metaplasia is not a Strong Risk Factor for Bladder Cancer: Study of 53 Cases with Long-term Follow-up. Urology 1997 Sept; 50(3):427–31.
190. ***Bostwick DG***, Pacelli A, Lopez-Beltran A. Ultrastructure of Prostate Intraepithelial Neoplasia. Prostate 1997 Sept; 15;33(1):32–7.
191. Helpap B, Bonkhoff H, Cockett A, Montironi R, Troncoso P, Waters D, ***Bostwick DG***. Relationship between Atypical Adenomatous Hyperplasia (AAH), Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma. Pathologica 1997; 89:288–300.
192. Chuaqui RF, Englert CR, Strup SE, Vocke CD, Zhuang Z, Duray PH, ***Bostwick DG***, Linehan, WM, Liotta, LA. Identification of a Novel Transcript Up-Regulated in a Clinically Aggressive Prostate Carcinoma. Urology 1997 Aug; 50(2):302–7.
193. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell RT, Shell BK, ***Bostwick DG***, Tindall DJ, Gelmann EP, Abate-Shen C, Carter KC. A Novel Human Prostate-Specific, Androgen-Regulated Homeobox Gene (NKX3.1) that Maps to 8p21, a Region Frequently Deleted in Prostate Cancer. Genomics 1997 Jul; 1;43(1):69–77.
194. Brown JA, Anderl KL, Borell TJ, Qian J, ***Bostwick DG***. Simultaneous Chromosome 7 and 17 Gain and Sex Chromosome Loss Provide Evidence that Renal Metanephric Adenoma is Related to Papillary Renal Cell Carcinoma. J. of Urol. 1997 Aug; 158(2):370–4.
195. Roberts RO, Lieber MM, ***Bostwick DG***, Jacobsen SJ. A Review of Clinical and Pathological Prostatitis Syndromes. Urology 1997 Jun; 49(6):809–21.

196. Waters DJ, ***Bostwick DG***. The Canine Prostate is a Spontaneous Model of Intraepithelial Neoplasia and Prostate Cancer Progression. Anticancer Res. 1997 May–Jun; 17(3A):1467–70. Review.
197. Pisansky TM, MJ, ***Bostwick DG***. An Enhanced Prognostic System for Clinically Localized Carcinoma of the Prostate. Cancer 1997 Jun; 79(11):2154–61.
198. Blute ML, ***Bostwick DG***, Bergstralh BJ, Slezak JM, Martin SK, Amling CL, Zincke H. Anatomic Site-Specific Positive Margins in Organ-confined Prostate Cancer and its Impact on Outcome after Radical Prostatectomy. Urology 1997 Nov; 50(5):733–9.
199. MacLennan GT, Farrow GM, ***Bostwick DG***. Low-Grade Collecting Duct Carcinoma of the Kidney: Report of 13 Cases of Low-Grade Mucinous Tubulocystic Renal Carcinoma of Possible Collecting Duct Origin. Urology 1997 Nov; 50(5):679–84.
200. ***Bostwick DG***, Montironi R. Evaluating Radical Prostatectomy Specimens: Therapeutic and Prognostic Importance. Virchows Archiv. 1997 Jan; 430(1):1–16.
201. Cheng L, Bergstralh EJ, Chevillie JC, Slezak J, Corica FA, Zincke H, Blute ML, ***Bostwick DG***. Cancer Volume of Lymph Node Metastasis Predicts Progression in Prostate Cancer. Am. J. Surg. Pathol. 1998 Dec; 22(12):1491–1500.
202. Murphy GP, Elgamal AA, Su SL, ***Bostwick DG***, Holmes EH. Current Evaluation of the Tissue Localization and Diagnostic Utility of Prostate Specific Membrane Antigen. Cancer 1998 Dec; 1;83(11):2259–69.
203. Kay PA, Robb RA, ***Bostwick DG***. Prostate Cancer Microvessels: A Novel Method for Three-Dimensional Reconstruction and Analysis. Prostate 1998 Dec; 1;37(4):270–7.
204. Cheng L, Sebo TJ, Slezak J, Pisansky TM, Bergstralh EJ, Neumann RM, Iczkowski KA, Zincke H, ***Bostwick DG***. Predictors of Survival for Prostate Carcinoma Patients Treated with Salvage Radical Prostatectomy after Radiation Therapy. Cancer 1998 Nov; 15;83(10):2164–71.
205. Chevillie JC, Sebo TJ, Lager DJ, ***Bostwick DG***, Farrow GM. Cell Tumor of the Testis: A Clinicopathologic, DNA Content, and MIB-1 Comparison of Nonmetastasizing and Metastasizing Tumors. Am. J. Surg. Pathol. 1998 Nov; 22(11):1361–7.
206. ***Bostwick DG***, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L. Independent Origin of Multiple Foci of Prostatic Intraepithelial Neoplasia: Comparison with Matched Foci of Prostate Carcinoma. Cancer 1998 Nov; 1;83(9):1995–2002.
207. Qian J, Jenkins RB, ***Bostwick DG***. Determination of Gene and Chromosome Dosage in Prostatic Intraepithelial Neoplasia and Carcinoma. Anal. Quant. Cytol. Histo. 1998 Oct; 20(5):373–80.
208. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, ***Bostwick DG***. Diagnosis of “Suspicious for Malignancy” in Prostate Biopsies: Predictive Value for Cancer. Urology 1998; 51:749–758.

209. ***Bostwick DG***. Practical Clinical Application of Predictive Factors in Prostate Cancer: A Review with an Emphasis on Quantitative Methods in Tissue Specimens. Anal. Quant. Cytol. Histol. 1998 Oct; 20(5):323–342.
210. Iczkowski KA, ***Bostwick DG***. The Pathologist as Optimist: Cancer Grade Deflation in Prostatic Needle Biopsies. Am. J. Surg. Pathol. 1998 Oct; 22(10):1169–70.
211. Sweat SD, Pacelli A, Murphy GP, ***Bostwick DG***. Prostate-Specific Membrane Antigen Expression is Greatest in Prostate Adenocarcinoma and Lymph Node Metastases. Urology 1998 Oct; 52(4):637–40.
212. ***Bostwick DG***, Iczkowski KA. Microvessel Density in Prostate Cancer: Prognostic and Therapeutic Utility. Semin. Urol. Oncol. 1998 Aug; 16(3):118–23.
213. Burke HB, ***Bostwick DG***. ProstAsure Index in the Detection of Prostate Cancer. Urology 1998 Sept; 52(3):531–2.
214. Iczkowski KA, ***Bostwick DG***, Roche PC, Cheville JC. Inhibin A is a Sensitive and Specific Marker for Testicular Sex Cord-Stromal Tumors. Mod. Pathol. 1998 Aug; 11(8):774–9.
215. ***Bostwick DG***, Iczkowski KA, Amin MB, Discigil G, Osborne B. Malignant Lymphoma Involving the Prostate: Report of 62 Cases. Cancer 1998 Aug; 15;83(4):732–8.
216. Aquilina JW, McKinney L, Pacelli A, Richman LK, Waters DJ, Thompson I, Burghardt WF, Jr., ***Bostwick DG***. High Grade Prostatic Intraepithelial Neoplasia in Military Working Dogs with and without Prostate Cancer. Prostate 1998 Aug; 1;36(3):189–93.
217. Cheng L, Neumann RM, Blute ML, Zincke H, ***Bostwick DG***. Long-term Follow-up of Untreated Stage T1: A Prostate Cancer. J. Natl. Cancer Inst. 1998 Jul; 15;90(14):1105–7.
218. Lucia MS, ***Bostwick DG***, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA. Workgroup I: Rodent Models of Prostate Cancer. Prostate 1998 Jun; 15;36(1):49–55.
219. Waters DJ, ***Bostwick DG***, Murphy GP. Conference Summary: First International Workshop on Animal Models of Prostate Cancer. Prostate 1998 Jun; 15;36(1):47–8.
220. Eid MA, Kumar MV, Iczkowski KA, ***Bostwick DG***, Tindall DJ. Expression of Early Growth Response Genes in Human Prostate Cancer. Can. Res. 1998 Jun; 1;58(11):2461–68.
221. ***Bostwick DG***, Pacelli A, Blute M, Roche P, Murphy GP. Prostate Specific Membrane Antigen Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Study of 184 Cases. Cancer 1998 Jun; 1;82(11):2256–61.
222. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, ***Bostwick DG***. Diagnosis of "Suspicious for Malignancy" in Prostate Biopsies: Predictive Value for Cancer. Urology 1998 May; 51(5):749–57.
223. Iczkowski KA, Shanks JH, ***Bostwick DG***. Loss of CD44 Variant 6 Expression Differentiates Small Cell Carcinoma of Urinary Bladder from Urothelial (transitional cell) Carcinoma. Histopathology 1998 Apr; 32(4):322–7.

224. Iczkowski KA, **Bostwick DG**. Detection of Early Prostate Cancer: Serendipitous or Systematic? JAMA 1998 May; 13; 279(18):1439; Author Reply 1441.
225. Pacelli A, Lopez-Beltran A, Egan AJ, **Bostwick DG**. Prostatic Adenocarcinoma with Glomeruloid Features. Hum. Pathol. 1998 May; 29(5):543–6.
226. Roberts RO, Lieber MM, Rhodes T, Girman CJ, **Bostwick DG**, Jacobsen SJ. Prevalence of a Physician-Assigned Diagnosis of Prostatitis: The Olmsted County Study of Urinary Symptoms and Health Status among Men. Urology 1998 Apr; 51(4):578–84.
227. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, **Bostwick DG**, Zincke H. Influence of Prostate-Specific Antigen Testing on the Spectrum of Patients with Prostate Cancer Undergoing Radical Prostatectomy at a Large Referral Practice. Mayo Clin. Proc. 1998 May; 73(5):401–6.
228. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, **Bostwick DG**, Lohse CM, Wollan P. Expression of p27kip1 in Prostatic Adenocarcinoma. Mod. Pathol. 1998 Apr; 11(4):324–8.
229. Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, **Bostwick DG**. Carcinosarcoma and Sarcomatoid Carcinoma of the Bladder: Clinicopathological Study of 41 Cases. J. Urol. 1998 May; 159(5):1497–503.
230. **Bostwick DG**, Murphy GP. Diagnosis and Prognosis of: Highlights from an International Consensus Workshop. Semin. Urol. Oncol. 1998 Feb; 16(1):46–52.
231. Blute ML, **Bostwick DG**, Seay TM, Martin SK, Slezak JM, Bergstralh EJ, Zincke H. Pathologic Classification of Prostate Carcinoma: The Impact of Margin Status. Cancer 1998 Mar; 1;82(5):902–8.
232. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, **Bostwick DG**, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI. A Molecular Cytogenetic Analysis of 7q31 in Prostate Cancer. Can. Res. 1998 Feb; 15;58(4):759–66.
233. Cheville JC, Dundore PA, **Bostwick DG**, Lieber MM, Batts KP, Sebo TJ, Farrow GM. Transitional Cell Carcinoma of the Prostate: Clinicopathologic Study of 50 Cases. Cancer 1998; 82(4):703–7.
234. Cheng L, Shan A, Cheville JC, Qian J, **Bostwick DG**. Atypical Adenomatous Hyperplasia of the Prostate: A Premalignant Lesion? Can. Res. 1998 Feb; 1;58(3):389–91.
235. Gettman MT, Bergstralh EJ, Blute M, Zincke H, **Bostwick DG**. Prediction of Patient Outcome in Pathologic Stage T2 Adenocarcinoma of the Prostate: Lack of Significance for Microvessel Density Analysis. Urology 1998 Jan; 51(1):79–85.
236. Aquilina JW, McKinney L, Pacelli A, Richman LK, Waters DJ, Thompson I, Burghardt WF, Jr., **Bostwick DG**. High Grade Prostatic Intraepithelial Neoplasia in Military Working Dogs with and without Prostate Cancer. Urology 1998; 36:189–193.
237. Qian J, Jenkins RB, **Bostwick DG**. Determination of Gene and Chromosome Dosage in Prostatic Intraepithelial Neoplasia and Carcinoma. Anal. Quant. Cytol. Histol. 1998; 20(5):373–80.

238. ***Bostwick DG***. Prostatic Adenocarcinoma Following Androgen Deprivation Therapy: The New Difficulty in Histologic Interpretation. Anat. Path. 1998; 3:1–16. Review.
239. Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zinke H, ***Bostwick DG***. Predictors of Cancer Progression in T1 a Prostate Adenocarcinoma. Cancer. 1999 Mar; 15;85(6):1300–4.
240. Burke HH, ***Bostwick DG***. ProstAsure Index in the Detection of Prostate Cancer. Urology 1999.
241. Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, ***Bostwick DG***. Correlation of Margin Status and Extraprostatic Extension with Progression of Prostate Carcinoma. Cancer 1999 Nov; 1;86(9): 1775–82.
242. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, ***Bostwick DG***, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 Tyrosine Kinase in Prostate Cancer. Prostate 1999 Dec; 1;41(4):275–80.
243. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zinke H, ***Bostwick DG***. Cell Proliferation in Prostate Cancer Patients with Lymph Node Metastasis: A Marker for Progression. Clin. Can. Res. 1999 Oct; 5(10):2820–2823.
244. Cheng L, Chevillie JC, ***Bostwick DG***. Diagnosis of Prostate Cancer in Needle Biopsies after Radiation Therapy. Am. J. Surg. Pathol. 1999 Oct; 23(10):1173–83.
245. Cheng L, Neumann RM, Weaver AL, Spotts BE, ***Bostwick DG***. Predicting Cancer Progression in Patients with Stage T1 Bladder Carcinoma. J. Clin. Oncol. 1999 Oct; 17(10):3182–3187.
246. ***Bostwick DG***, Eble JN. Diagnosis and Classification of Renal Cell Carcinoma. Urol. Clin. N. Am. 1999 Aug; 26(3):627–35.
247. ***Bostwick DG***, Ramnani D, Cheng L. Diagnosis and Grading of Bladder Cancer and Associated Lesions. Urol. Clin. N. Am. 1999 Aug; 26(3):493–507.
248. ***Bostwick DG***, Ramnani D, Cheng L. Treatment Changes in Prostatic Hyperplasia and Cancer, Including Androgen Deprivation Therapy and Radiotherapy. Urol. Clin. N. Am. 1999 Aug; 26(3):465–79.
249. Iczkowski KA, ***Bostwick DG***. Prostate Biopsy Interpretation: Current Concepts, 1999; Urol. Clin. N. Am. 1999 Aug; 26(3):435–52.
250. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, ***Bostwick DG***, Grizzle WE. Ep-Cam Levels in Prostatic Adenocarcinoma and Prostatic Intraepithelial Neoplasia. J. Urol. 1999 Oct; 162(4):1462–6.
251. Cheng L, Weaver AL, Neumann RM, Scherer BG, ***Bostwick DG***. Substaging of T1 Bladder Carcinoma Based on the Depth of Invasion as Measured by Micrometer: A New Proposal. Cancer 1999 Sept; 15;86(6):1035–43.
252. Magi-Galluzzi C, Nagy S, ***Bostwick DG***, Cheng L, Gould VE. Demonstrability of the Glycoprotein A-80 in Postradiation Prostatic Carcinoma. Hum. Pathol. 1999 Dec; 30(12):1474–78.
253. Iczkowski KA, Cheng L, Qian J, Shanks J, Gadaleanu V, ***Bostwick DG***, Ramnani DM. ASAP is a Valid Diagnosis: Atypical Small Acinar Proliferation. Hum. Pathol. 1999 Dec; 30(12):1403–4.



254. ***Bostwick DG***, Foster CS. Prostatic Intraepithelial Neoplasia is a Risk Factor for Cancer. Semin.Urol. Oncol. 1999; 17(4):187–98.
255. Brawer MK, Benson MC, ***Bostwick DG***, Djavan B, Lilja H, Semjonow A, Su S, Zhou Z. Prostate-Specific Antigen and Other Serum Markers: Current Concepts from the World Health Organization Second International Consultation on Prostate Cancer. Semin. Urol. Oncol. 1999 Nov; 17(4):206–21.
256. ***Bostwick DG***, Chang L. Over-diagnosis of Prostatic Adenocarcinoma. Semin. Urol. Oncol. 1999 Nov; 17(4):199–205.
257. ***Bostwick DG***. Prostatic Intraepithelial Neoplasia is a Risk Factor for Cancer. Semin. Urol. Oncol. 1999 Nov; 17(4):187–98.
258. Iczkowski KA, ***Bostwick DG***. Prostate Biopsy 1999: Strategies and Significance of Pathological Findings. Semin. Urol. Oncol. 1999 Nov; 17(4):177–86.
259. Cheng L, ***Bostwick DG***. Progression of T1 Bladder Tumors: Better Staging or Better Biology? Reply. Cancer 1999 Sept; 15;86(6):910–2.
260. Cheng L, Scheithauer BW, Leibovich BC, Ramnani DM, Cheville JC, ***Bostwick DG***. Neurofibroma of the Urinary Bladder. Cancer 1999 Aug; 1;86(3):505–13.
261. Cheng L, Nascimento AG, Neumann RM, Nehra A, Cheville JC, Ramnani DM, Leibovich BC, ***Bostwick DG***. Hemangioma of the Urinary Bladder. Cancer 1999 Aug; 1;86(3):498–504.
262. Cheng L, Montironi R, ***Bostwick DG***. Villous Adenoma of the Urinary Tract: A Report of 23 Cases, Including 8 with Coexistent Adenocarcinoma. Am. J. Surg. Pathol. 1999 Jul; 23(7):764–71.
263. Cheng L, Cheville JC, Pisansky TM, Sebo TJ, Slezak J, Bergstralh EJ, Neumann RM, Singh R, Pacelli A, Zincke H, ***Bostwick DG***. Prevalence and Distribution of Prostatic Intraepithelial Neoplasia in Salvage Radical Prostatectomy Specimens after Radiation Therapy. Am J Surg Pathol. 1999 Jul; 23(7):803–8.
264. Khair AA, Pacelli A, Iczkowski KA, Cheng L, Corica FA, Larson TR, Corica A, ***Bostwick DG***. Does Transurethral Microwave Thermotherapy Have a Different Effect on Prostate Cancer than on Benign or Hyperplastic Tissue? Urology 1999 Jul; 54(1):67–72.
265. Cheng L, Neumann RM, Scherer BG, Weaver AL, Leibovich BC, Nehra A, Zincke H, ***Bostwick DG***. Tumor Size Predicts the Survival of Patients with Pathologic Stage T2 Bladder Carcinoma: A Critical Evaluation of the Depth of Muscle Invasion. Cancer 1999 June; 15;85(12):2638–47.
266. Cheng L, Cheville JC, Neumann RM, Leibovich BC, Egan KS, Spotts BE, ***Bostwick DG***. Survival of Patients with Carcinoma In Situ of the Urinary Bladder. Cancer 1999 Jun; 1;85(11):2469–74.
267. Cheng L, Leibovich BC, Bergstralh EJ, Scherer BG, Pacelli A, Ramnani DM, Zincke H, ***Bostwick DG***. p53 Alteration in Regional Lymph Node Metastases from Prostate Carcinoma: A Marker for Progression? Cancer 1999 Jun; 1;85(11):2455–59.
268. Cheng L, ***Bostwick DG***, Li G, Wang Q, Hu N, Vortmeyer AO, Zhuang Z. Allelic Imbalance in the Clonal Evolution of Prostate Carcinoma. Cancer 1999 May; 1;85(9):2017–22.

269. Ramnani DM, ***Bostwick DG***. Basal Cell-Specific Anti-Keratin Antibody 34betaE12: Optimizing its use in Distinguishing Benign Prostate and Cancer. Mod. Pathol. 1999 May; 12(5):443–4.
270. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, Young CY, Klee GG, Tindall DJ, ***Bostwick DG***. Kallikrein Expression in Prostate Adenocarcinoma and Lymph Node Metastases. Urology 1999 May; 53(5):939–44.
271. Yokomizo A, Mai M, ***Bostwick DG***, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI, Liu W. Mutation and Expression Analysis of the p73 Gene in Prostate Cancer. Prostate 1999 May; 39(2):94–100.
272. Cheng L, JC, Neumann RM, ***Bostwick DG***. Natural History of Urothelial Dysplasia of the Bladder. Am. J. Surg. Pathol. 1999 Apr; 23(4):443–7.
273. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, ***Bostwick DG***. Androgen Receptor Expression in Prostate Cancer Lymph Node Metastases is Predictive of Outcome after Surgery. J. Urol. 1999 Apr; 161(4):1233–7.
274. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, ***Bostwick DG***. Androgen Receptor Expression in Prostatic Intraepithelial Neoplasia and Cancer. J. Urol. 1999 Apr; 161(4):1229–32.
275. Cheng L, Sebo TJ, Chevillie JC, Pisansky TM, Slezak J, Bergstralh EJ, Pacelli A, Neumann RM, Zincke H, ***Bostwick DG***. p53 Protein Overexpression is Associated with Increased Cell Proliferation in Patients with Locally Recurrent Prostate Carcinoma after Radiation Therapy. Cancer 1999 Mar; 15;85(6):1293–99.
276. Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, ***Bostwick DG***. P53 Protein Overexpression is Associated with Increased Cell Proliferation in Patients with Locally Recurrent Prostate Carcinoma after Radiation Therapy. Cancer. 1999; 85(6):1293–99.
277. Corica FA, Jacobsen SJ, King BF, ***Bostwick DG***, Jacobson DJ, Girman CJ, Lieber MM. Lower Urinary Tract Symptom Severity and Peak Urinary Flow Rates in Community Dwelling Men. J. Urol. 1999 Mar; 161(3):831–4.
278. Corica FA, ***Bostwick DG***. Clinically Unsuspected and Undetected (Clinical Stage t0) Prostate Cancer Diagnosed in Random Needle Biopsy. Urology 1999 Mar; 53(3):557–60.
279. Yokomizo A, Mai M, Tindall DJ, Cheng L, ***Bostwick DG***, Naito S, Smith DI, Liu W. Overexpression of the Wild Type p73 Gene in Human Bladder Cancer. Oncogene 1999 Feb; 25;18(8):1629–33.
280. Colby TV, ***Bostwick DG***. Sarcomas and Related Proliferative Lesions of Specialized Prostatic Stroma. Am. J. Surg. Pathol. 1999 Feb; 23(2):243–4.
281. Corica FA, Iczkowski KA, Cheng L, Zincke H, Blute ML, Wendel A, Sebo TJ, Neumann R, ***Bostwick DG***. Cystic Renal Cell Carcinoma is Cured by Resection: A Study of 24 Cases with Long-term Follow-up. J Urol. 1999 Feb; 161(2):408–11.
282. Iczkowski KA, Sweat SD, ***Bostwick DG***. Subepithelial Pelvic Hematoma of the Kidney Clinically Mimicking Cancer: Report of Six Cases and Review of the Literature. Urology 1999 Feb; 53(2):276–9.

283. Mohan RR, Challa A, Gupta S, **Bostwick DG**, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H. Overexpression of Ornithine Decarboxylase in Prostate Cancer and Prostatic Fluid in Humans. Clin. Can. Res. 1999 Jan; 5(1):143–7.
284. Iczkowski KA, Cheng L, Crawford BG, **Bostwick DG**. Steam Heat with an EDTA Buffer and Protease Digestion Optimizes Immunohistochemical Expression of Basal Cell-Specific Antikeratin 34betaE12 to Discriminate Cancer in Prostatic Epithelium. Mod. Pathol. 1999 Jan; 12(1):1–4.
285. Qian J, Jenkins RB, **Bostwick DG**. Genetic and Chromosomal Alterations in Prostatic Intraepithelial Neoplasia and Carcinoma Detected by Fluorescence In Situ Hybridization. Eur. Urol. 1999; 35(5–6):479–83.
286. **Bostwick DG**, Neumann R, Qian J, Cheng L. Reversibility of Prostatic Intraepithelial Neoplasia: Implications for Chemoprevention. Eur. Urol. 1999; 35(5–6):492–5.
287. Grignon DJ, **Bostwick DG**, Civantos F, Garnick MB, Gaudin P, Srigley JR. Pathologic Handling and Reporting of Prostate Tissue Specimens in Patients Receiving Neoadjuvant Hormonal Therapy: Report of the Pathology Committee. Mol. Urol. 1999; 3(3):193–198.
288. Sato K, Qian J, Slezak JM, Lieber MM, **Bostwick DG**, Bergstralh EJ, Jenkins RB. Clinical Significance of Alterations of Chromosome 8 in High-Grade, Advanced, Nonmetastatic Prostate Carcinoma. J. Natl. Can. Inst. 1999 Sept; 15;91(18):1574–80.
289. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, **Bostwick DG**. Role of Microvessel Density in Predicting Recurrence in Pathologic Stage T3 Prostatic Adenocarcinoma. Urology 1999 Sept; 54(3):479–85.
290. **Bostwick DG**. What is the Significance of Race to Prostate Carcinoma? Cancer 1999 Sept; 1;86(5):735–7.
291. Iczkowski KA, Shanks JH, Allsbrook WC, Lopez-Beltran A, Pantazis CG, Collins TR, Wetherington RW, **Bostwick DG**. Small Cell Carcinoma of Urinary Bladder is Differentiated from Urothelial Carcinoma by Chromogranin Expression, CD44 Variant 6 Expression, a Unique Pattern of Cytokeratin Expression, and More Intense Gamma-Enolase Expression. Histopath. 1999 Aug; 35(2):150–6.
292. Alfonzo A, Emmert-Buck MR, Duray PH, **Bostwick DG**, Linehan WM, Vocke CD. Loss of Heterozygosity on Chromosome 13 is Associated with Advanced Stage Prostate Cancer. J. Urol. 1999 Sept; 162(3 Pt 1):922–6.
293. Nehra A, Gettman MT, Nugent M, **Bostwick DG**, Barrett DM, Goldstein I, Krane RJ, Moreland RB. Transforming Growth Factor-Beta 1 (TGF-beta1) is Sufficient to Induce Fibrosis of Rabbit Corpus Cavernosum In Vivo. J. Urol. 1999 Sept; 162(3 Pt 1):910–5.
294. Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, **Bostwick DG**. Dedifferentiation in the Metastatic Progression of Prostate Carcinoma. Cancer 1999 Aug; 15;86(4):657–63.
295. Strup SE, Pozzatti RO, Florence CD, Emmert-Buck MR, Duray PH, Liotta LA, **Bostwick DG**, Linehan WM, Vocke CD. Chromosome 16 Allelic Loss Analysis

- of a Large Set of Microdissected Prostate Carcinomas. *J. Urol.* 1999 Aug; 162(2):590–594
296. Bock BJ, ***Bostwick DG***. Does Prostatic Ductal Adenocarcinoma Exist? *Am. J. Surg. Pathol.* 1999 Jul; 23:781–785.
  297. Dechet CB, ***Bostwick DG***, Blute ML, Bryant SC, Zincke H. Renal Oncocytoma: Multifocality, Bilateralism, Metachronous Tumor Development and Coexistent Renal Cell Carcinoma. *J. Urol.* 1999 Jul; 162:40–42.
  298. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, ***Bostwick DG***. The Radial Distance of Extraprostatic Extension of Prostate Carcinoma: Implications for Prostate Brachytherapy. *Cancer* 1999 Jun; 15;85(12):2630–2637.
  299. ***Bostwick DG***, Neumann R, Qian J, Cheng L. Reversibility of Prostatic Intraepithelial Neoplasia: Implications for Chemoprevention. *Eur. Urol.* 1999; 35:492–495.
  300. Cheng L, Neumann RM, ***Bostwick DG***. Papillary Urothelial Neoplasms of Low Malignant Potential: Clinical and Biologic Implications. *Cancer* 1999 Nov; 15;86:2102–2108.
  301. Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A, ***Bostwick DG***. Urothelial Papilloma of the Bladder: Clinical and Biologic Implications. *Cancer* 1999 Nov; 15;86(10):2098–2101.
  302. Mohammed SI, Knapp DW, ***Bostwick DG***, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. Expression of Cyclooxygenase-2 (COX-2) in Human Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder. *Can. Res.* 1999 Nov; 59:5647–5650.
  303. ***Bostwick DG***, Foster CS. Predictive Factors in Prostate Cancer: Current Concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. *Semin. Urol. Oncol.* 1999 Nov; 17(4):222–72. Review.
  304. Cheng L, Pisansky TM, Ramnani DM, Leibovich BC, Cheville JC, Slezak J, Bergstrahl EJ, Zincke H, ***Bostwick DG***. Extranodal Extension in Lymph Node-Positive Prostate Cancer. *Mod. Pathol.* 2000 Feb; 13(2):113–8.
  305. Cheng L, Cheville JC, Sebo TJ, Eble JN, ***Bostwick DG***. Atypical Nephrogenic Metaplasia of the Urinary Tract: A Precursor Lesion? *Cancer* 2000 Feb; 88(4):853–61.
  306. ***Bostwick DG***, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD. Antioxidant Enzyme Expression and Reactive Oxygen Species Damage in Prostatic Intraepithelial Neoplasia and Cancer. *Cancer* 2000 Jul; 1:89(1):123–34.
  307. Leibovich BC, Cheng L, Weaver AL, Myers RP, ***Bostwick DG***. Outcome Prediction with p53 Immunostaining after Radical Prostatectomy in Patients with Locally Advanced Prostate Cancer. *J. Urol.* 2000 Jun; 163(6):1756–60.
  308. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, ***Bostwick DG***. The Cell Cycle Inhibitors p21WAF1 and p27KIP1 are Associated with Survival in Patients Treated by

- Salvage Prostatectomy after Radiation Therapy. Clin. Can. Res. 2000 May; 6(5):1896–9.
309. Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, ***Bostwick DG***, Brown MR, Buetow KH, Chuaqui RF, Cole KA, Duray PH, Englert CR, Gillespie JW, Greenhut S, Grouse L, Hillier LW, Katz KS, Klausner RD, Kuznetzov V, Lash AE, Lennon G, Linehan WM, Liotta LA, Marra MA, Munson PJ, Ornstein DK, Prabhu VV, Prang C, Schuler GD, Soares MB, Tolstoshev CM, Vocke CD, Waterston RH. Molecular Profiling of Clinical Tissue Specimens: Feasibility and Applications. J. Mol. Diagn. 2000 May; 2(2):60–6.
  310. ***Bostwick DG***. Prostatic Intraepithelial Neoplasia. Curr. Urol. Rep. 2000 May; 1(1):65–70.
  311. ***Bostwick DG***, Ramnani D, Qian J. Prostatic Intraepithelial Neoplasia: Animal Models 2000. Prostate 2000 Jun; 43(4):286–94.
  312. Cheng L, Weaver AL, Leibovich BC, Ramnani DM, Neumann RM, Scherer BG, Nehra A, Zincke H, ***Bostwick DG***. Predicting the Survival of Bladder Carcinoma Patients Treated with Radical Cystectomy. Cancer 2000 May; 88(10):2326–32.
  313. Davis BJ, Haddock MG, Wilson TM, Rothenberg HJ, ***Bostwick DG***, Herman MG, Pisansky TM. Treatment of Extraprostatic Cancer in Clinically Organ-Confining Prostate Cancer by Permanent Interstitial Brachytherapy: Is Extraprostatic Seed Placement Necessary? Tech. Urol. 2000 Jun; 6(2):70–7.
  314. Gupta S, Srivastava M, Ahmad N, ***Bostwick DG***, Mukhtar H. Over-Expression of Cyclooxygenase-2 in Human Prostate Adenocarcinoma. Prostate 2000 Jan; 42(1):73–78
  315. Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, ***Bostwick DG***, Brown MR, Buetow KH, Chuaqui RF, Cole KA, Duray PH, Englert CR, Gillespie JW, Greenhut S, Grouse L, Hillier LW, Katz KS, Klausner RD, Kuznetzov V, Lash AE, Lennon G, Linehan WM, Liotta LA, Marra MA, Munson PJ, Ornstein DK, Prabhu VV, Prange C, Schuler GD, Soares MB, Tolstoshev CM, Vocke CD, Waterston RH. Molecular Profiling of Clinical Tissue Specimens: Feasibility and Applications. Am. J. Pathol. 2000 Apr; 156(4):1109–15.
  316. Roberts RO, Bergstralh EJ, Peterson NR, ***Bostwick DG***, Lieber MM, Jacobsen SJ. Positive and Negative Biopsies in the Pre-Prostate Specific Antigen and Prostate Specific Antigen Eras, 1980 to 1997. J. Urol. 2000 May; 163(5):1471–5.
  317. Rubin MA, Gerstein A, Reid K, ***Bostwick DG***, Cheng L, Parsons R, Papadopoulos N. 10q23.3 Loss of Heterozygosity is Higher in Lymph Node-Positive (pT2-3,N+) Versus Lymph Node-Negative (pT2-3,N0) Prostate Cancer. Hum. Pathol. 2000 Apr; 31(4):504–8.
  318. Cheng L, ***Bostwick DG***. World Health Organization and International Society of Urological Pathology Classification and Two-Number Grading System of Bladder Tumors: Reply. Cancer 2000 Apr; 88(7):1513–6.

319. Montironi R, Mazzucchelli R, Algaba F, ***Bostwick DG***, Krongrad A. Prostate-Specific Antigen as a Marker of Prostate Disease. Virchows Arch. 2000 Apr; 436(4):297–304.
320. Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Neumann RM, Nascimento AG, Zincke H, ***Bostwick DG***. Paraganglioma of the Urinary Bladder: Can Biologic Potential Be Predicted? Cancer 2000 Feb; 15;8(4):844–52.
321. Cheng L, Neumann RM, Weaver AL, Cheville JC, Leibovich BC, Ramnani DM, Scherer BG, Nehra A, Zincke H, ***Bostwick DG***. Grading and Staging of Bladder Carcinoma in Transurethral Resection Specimens. Correlation with 105 Matched Cystectomy Specimens. Am. J. Clin. Pathol. 2000 Feb; 113(2):275–9.
322. Cheng L, Cheville JC, Neumann RM, ***Bostwick DG***. Flat Intraepithelial Lesions of the Urinary Bladder. Cancer 2000 Feb; 88(3):625–31.
323. Iczkowski KA, ***Bostwick DG***. Criteria for Biopsy Diagnosis of Minimal Volume Prostatic Adenocarcinoma: Analytic Comparison with Nondiagnostic but Suspicious Atypical Small Acinar Proliferation. Arch. Pathol. Lab. Med. 2000 Jan; 124(1):98–107.
324. Gupta S, Srivastava M, Ahmad N, ***Bostwick DG***, Mukhtar H. Over-Expression of Cyclooxygenase-2 in Human Prostate Adenocarcinoma. Prostate 2000; 42(1):73–78.
325. ***Bostwick DG***, Montironi R, Sesterhenn IA. Diagnosis of Prostatic Intraepithelial Neoplasia: Prostate Working Group/Consensus Report. Scand. J. Urol. Nephrol. Suppl. 2000; (205):3–10.
326. ***Bostwick DG***, Norlen BJ, Denis L. Prostatic Intraepithelial Neoplasia: The Preinvasive Stage of Prostate Cancer. Overview of the Prostate Committee Report. Scand. J. Urol. Nephrol. Suppl. 2000; (205):1–2.
327. Foster CS, ***Bostwick DG***, Bonkhoff H, Damber JE, van der Kwast T, Montironi R, Sakr WA. Cellular and Molecular Pathology of Prostate Cancer Precursors. Scand. J. Urol. Nephrol. Suppl. 2000; (205):19–43.
328. Sakr WA, Billis A, Ekman P, Wilt T, ***Bostwick DG***. Epidemiology of High-Grade Prostatic Intraepithelial Neoplasia. Scand. J. Urol. Nephrol. Suppl. 2000; (205):11–8.
329. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, ***Bostwick DG***, Linehan WM, Petricoin EF 3rd, Emmert-Buck MR. Proteomic Analysis of Laser Capture Microdissected Human Prostate Cancer and In Vitro Prostate Cell Lines. Electrophoresis 2000 Jun; 21(11):2235–42.
330. Corica FA, Cheng L, Ramnani D, Pacelli A, Weaver A, Corica AP, Corica AG, Larson TR, O'Toole K, ***Bostwick DG***. Transurethral Hot-Water Balloon Thermoablation for Benign Prostatic Hyperplasia: Patient Tolerance and Pathologic Findings. Urology 2000 Jul; 56(1):76–80.
331. ***Bostwick DG***, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospodarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbrow JW. Prognostic Factors in Prostate Cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 2000 Jul; 124(7):995–1000.

332. ***Bostwick DG***. Immunohistochemical Changes in Prostate Cancer after Androgen Deprivation Therapy. Mol. Urol. 2000 Fall; 4(3):101–106.
333. Leibovich BC, Blute ML, ***Bostwick DG***, Wilson TM, Pisansky TM, Davis BJ, Ramnani DM, Cheng L, Sebo TJ, Zincke H. Proximity of Prostate Cancer to the Urethra: Implications for Minimally Invasive Ablative Therapies. Urology 2000 Nov; 56(5):726–29.
334. Cornell KK, ***Bostwick DG***, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, Waters DJ. Clinical and Pathologic Aspects of Spontaneous Canine Prostate Carcinoma: A Retrospective Analysis of 76 Cases. Prostate 2000 Oct; 45(2):173–83.
335. Schellhammer PF, Moriarty R, ***Bostwick DG***, Kuban D. Fifteen-Year Minimum Follow-up of a Prostate Brachytherapy Series: Comparing the Past with the Present. Urology 2000; 56(3):436–9.
336. Seelan RS, Qian C, Yokomizo A, ***Bostwick DG***, Smith DI, Liu W. Human Acid Ceramidase is Overexpressed but not Mutated in Prostate Cancer. Genes Chrom. Can. 2000 Oct; 29(2):137–46.
337. Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, ***Bostwick DG***. Preoperative Prediction of Surgical Margin Status in Patients with Prostate Cancer Treated by Radical Prostatectomy. J. Clin. Oncol. 2000 Aug; 18(15):2862–8.
338. Halmos G, Schally AV, Sun B, Davis R, ***Bostwick DG***, Plonowski A. High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers. J. Clin. Endoc. Metab. 2000 Jul; 85(7):2564–71.
339. Cheng L, Weaver AL, ***Bostwick DG***. Predicting Extravesical Extension of Bladder Carcinoma: A Novel Method Based on Micrometer Measurement of the Depth of Invasion in Transurethral Resection Specimens. Urology 2000 May; 55(5):668–72.
340. Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Nehra A, Malek RS, Zincke H, ***Bostwick DG***. Squamous Papilloma of the Urinary Tract is Unrelated to Condyloma Acuminata. Cancer 2000 Apr; 88(7):1679–86.
341. Iczkowski KA, ***Bostwick DG***. Sampling, Submission, and Report Format for Multiple Prostate Biopsies: A 1999 Survey. Urology 2000 Apr; 55(4):568–71.
342. Larson TR, Robertson DW, Corica A, ***Bostwick DG***. In Vivo Interstitial Temperature Mapping of the Human Prostate during Cryosurgery with Correlation to Histopathologic Outcomes. Urology 2000 Apr; 55(4):547–52.
343. Halmos G, Arencibia JM, Schally AV, Davis R, ***Bostwick DG***. High Incidence of Receptors for Luteinizing Hormone-Releasing Hormone (LHRH) and LHRH Receptor Gene Expression in Human Prostate Cancers. J. Urol. 2000 Feb; 163(2):623–9.
344. Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, ***Bostwick DG***. Cancer Heterogeneity and its Biologic Implications in the Grading of Urothelial Carcinoma. Cancer. 2000 Apr; 88(7):1663–70.
345. Srigley JR, Amin MB, ***Bostwick DG***, Grignon DJ, Hammond ME. Updated Protocol for the Examination of Specimens from Patients with Carcinomas of

- the Prostate Gland: A Basis for Checklists. Cancer Committee, Arch. Pathol. Lab Med. 2000 Jul; 124(7):1034–9.
346. Collyer WC, Landman J, Olweny EO, Andreoni C, Kerbl K, ***Bostwick DG***, Clayman RV. Comparison of Renal Ablation with Cryotherapy, Dry Radiofrequency, and Saline Augmented Radiofrequency in a Porcine Model. J. Am. Coll. Surg. 2001 Nov; 193(5):505–13.
  347. Cheng L, Gu J, Eble JN, ***Bostwick DG***, Younger C, MacLennan GT, Abdul-Karim FW, Geary WA, Koch MO, Zhang S, Ulbright TM. Molecular Genetic Evidence for Different Clonal Origin of Components of Human Renal Angiomyolipomas. Am. J. Surg. Pathol. 2001 Oct; 25(10):1231–36.
  348. Iczkowski KA, Shanks JH, Gadaleanu V, Cheng L, Jones EC, Neumann R, Nascimento AG, ***Bostwick DG***. Inflammatory Pseudotumor and Sarcoma of Urinary Bladder: Differential Diagnosis and Outcome in Thirty-Eight Spindle Cell Neoplasms. Mod. Pathol. 2001 Oct; 14(10):1043–51.
  349. Lau WK, Blute ML, ***Bostwick DG***, Weaver AL, Sebo TJ, Zincke H. Prognostic Factors for Survival of Patients with Pathological Gleason Score 7 Prostate Cancer: Differences in Outcome between Primary Gleason Grades 3 and 4. J. Urol. 2001 Nov; 166(5):1692–7.
  350. Cheng L, ***Bostwick DG***, Li G, Zhang S, Vortmeyer AO, Zhuang Z. Conserved Genetic Findings in Metastatic Bladder Cancer: A Possible Utility of Allelic Loss of Chromosomes 9p21 and 17p13 in Diagnosis. Arch. Pathol. Lab Med. 2001 Sept; 125(9):1197–9.
  351. ***Bostwick DG***, Qian J. Effect of Androgen Deprivation Therapy on Prostatic Intraepithelial Neoplasia. Urology 2001 Aug; 58 (2 Suppl.):91–3.
  352. Jiang J, Ulbright TM, Younger C, Sanchez K, ***Bostwick DG***, Koch MO, Eble JN, Cheng L. Cytokeratin 7 and Cytokeratin 20 in Primary Urinary Bladder Carcinoma and Matched Lymph Node Metastasis. Arch. Pathol. Lab. Med. 2001 Jul; 125(7):921–3.
  353. ***Bostwick DG***, Burke HB. Prediction of Individual Patient Outcome in Cancer: Comparison of Artificial Neural Networks and Kaplan-Meier Methods. Cancer. 2001 Apr; 91(8 Suppl.): 1643–6.
  354. Gupta S, Srivastava M, Ahmad N, Sakamoto K, ***Bostwick DG***, Mukhtar H. Lipoxigenase-5 is Overexpressed in Prostate Adenocarcinoma. Cancer. 2001 Feb; 91(4):737–43.
  355. Allsbrook WC, Jr., Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, ***Bostwick DG***, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI. Interobserver Reproducibility of Gleason Grading of Prostatic Carcinoma: Urologic Pathologists. Hum. Pathol. 2001 Jan; 32(1):74–80.
  356. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, ***Bostwick DG***. Risk of Prostate Carcinoma Death in Patients with Lymph Node Metastasis. Cancer. 2001 Jan; 91(1):66–73.
  357. Collyer WC, Landman J, Olweny EO, Andreoni C, Kibel A, Andriole GL, ***Bostwick DG***, Sundaram CP, Clayman RV. Laparoscopic Partial Nephrectomy with a Novel Electrosurgical Snare in a Porcine Model. J. Endourol. 2002 Nov; 16(9):673–9.



358. Polascik TJ, ***Bostwick DG***, Cairns P. Molecular Genetics and Histopathologic Features of Adult Distal Nephron Tumors. *Urology*. 2002 Dec; 60(6):941–46.
359. Rehman J, Landman J, Tucker RD, ***Bostwick DG***, Sundaram CP, Clayman RV. Ferromagnetic Self-Regulating Reheatable Thermal Rod Implants for In Situ Tissue Ablation. *J. Endourol*. 2002 Sept; 16(7):523–31.
360. Lowry PW, Myers JD, Geller A, ***Bostwick DG***, Clain JE. Graft-versus-Host-like Colitis and Malignant Thymoma. *Dig. Dis. Sci*. 2002 Sept; 47(9):1998–2001.
361. ***Bostwick DG***, Mikuz G. Urothelial Papillary (Exophytic) Neoplasms. *Virchows Arch*. 2002 Aug; 441(2):109–16.
362. ***Bostwick DG***, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L. Neuroendocrine Expression in Node Positive Prostate Cancer: Correlation with Systemic Progression and Patient Survival. *J. Urol*. 2002 Sept; 168(3):1204–11.
363. Iczkowski KA, Casella G, Seppala RJ, Jones GL, Mishler BA, Qian J, ***Bostwick DG***. Needle Core Length in Sextant Biopsy Influences Prostate Cancer Detection Rate. *Urology*. 2002 May; 59(5):698–703.
364. Qian J, Hirasawa K, ***Bostwick DG***, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB. Loss of p53 and c-myc Overrepresentation in Stage T(2-3)N(1–3)M(0) Prostate Cancer are Potential Markers for Cancer Progression. *Mod. Pathol*. 2002 Jan; 15(1):35–44.
365. Swalwell JI, Vocke CD, Yang Y, Walker JR, Grouse L, Myers SH, Gillespie JW, ***Bostwick DG***, Duray PH, Linehan WM, Emmert-Buck MR. Determination of a Minimal Deletion Interval on Chromosome Band 8p21 in Sporadic Prostate Cancer. *Genes Chrom. Can*. 2002 Feb; 33(2):201–05.
366. Waters DJ, Shen S, Cooley DM, ***Bostwick DG***, Qian J, Combs GF Jr, Glickman LT, Oteham C, Schlittler D, Morris JS. Effects of Dietary Selenium Supplementation on DNA Damage and Apoptosis in Canine Prostate. *J. Natl. Can. Inst*. 2003 Feb; 5; 95(3):237–41.
367. Montironi R, Lopez-Beltran A, Mazzucchelli R, ***Bostwick DG***. Classification and Grading of the Non-Invasive Urothelial Neoplasms: Recent Advances and Controversies. *J. Clin. Pathol*. 2003 Feb; 56(2):91–5.
368. Coogan CL, ***Bostwick DG***, Bloom KJ, Gould VE. Glycoprotein A-80 in the Human Prostate: Immunolocalization in Prostatic Intraepithelial Neoplasia, Carcinoma, Radiation Failure, and after Neoadjuvant Hormonal Therapy. *Urology*. 2003 Jan; 61(1):248–52.
369. ***Bostwick DG***, De La Roza G, Dundore P, Corica FA. Intraepithelial and Stromal Lymphocytes in the Normal Human Prostate. *Prostate*. 2003 May; 55(3):187–93.
370. ***Bostwick DG***, Schlesinger C. Contemporary Pathology of Prostate Cancer. *Urol. Clin. North Am*. 2003 May; 30(2):181–207.
371. Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, ***Bostwick DG***, Linehan WM, Emmert-Buck MR. Molecular Differentiation of High- and Moderate-Grade Human Prostate Cancer cFNA Microarray Analysis. *Diag. Mol. Pathol*. 2003 Jun; 12(2):63–70.

372. Larson BT, ***Bostwick DG***, Corica AG, Larson TR. Histological Changes of Minimally Invasive Procedures for the Treatment of Benign Prostatic Hyperplasia and Prostate Cancer: Clinical Implications. *J. Urol.* 2003 Jul; 170(1):12–9.
373. ***Bostwick DG***, Qian J, Ma J, Muir TE. Mesonephric Remnants of the Prostate: Incidence and Histologic Spectrum. *Mod. Pathol.* 2003 Jul; 16(7):630–5.
374. Corica AG, Qian J, Ma J, Sagaz AA, Corica AP, ***Bostwick DG***. Fast Liquid Ablation System for Prostatic Hyperplasia: A New Minimally Invasive Thermal Treatment. *J. Urol.* 2003 Sept; 170(3):874–8.
375. Abrams NA, ***Bostwick DG***, Ormsby AH, Qian J, Brainard JA. Distinguishing Atrophy and High-Grade Prostatic Intraepithelial Neoplasia from Prostatic Adenocarcinoma with and without Previous Adjuvant Hormone Therapy with the Aid of Cytokeratin 5/6. *Am. J. Clin. Pathol.* 2003 Sept; 120(3):368–76.
376. Montironi R, Scarpelli M, Mazzucchelli R, Hamilton P, Thompson D, Ranger-Moore J, ***Bostwick DG***, Bartels P. Subvisual Changes in Chromatin Organization State are Detected by Karyometry in the Histologically Normal Urothelium in Patients with Synchronous Papillary Carcinoma. *Hum. Pathol.* 2003 Sept; 34(9):893–901.
377. Larson BT, Collins JM, Huidobro C, Coria A, Vallejo S, ***Bostwick DG***. Gadolinium-Enhanced MRI in the Evaluation of Minimally Invasive Treatment of the Prostate: Correlation with Histopathologic Findings. *Urol.* 2003 Nov; 62(5):900–4.
378. Iczkowski KA, Gerguson KL, Grier DD, Hossain D, Banerjee SS, McNeal JE, ***Bostwick DG***. Adenoid Cystic/Basal Cell Carcinoma of the Prostate: Clinicopathologic Findings in 19 Cases. *Am. J. Surg. Pathol.* 2003 Dec; 27(12):1523–9.
379. Rehman J, Landman J, Lee D, Venkatesh R, ***Bostwick DG***, Sundaram C, Clayman RV. Needle-Based Ablation of Renal Parenchyma Using Microwave, Cryoablation, Impedance and Temperature-based Monopolar and Bipolar Radiofrequency, a Liquid and Gel Chemoblation: Laboratory Studies and Review of the Literature. *J. Endourol.* 2004 Feb; 18(1):83–104.
380. ***Bostwick DG***, Qian J, Maihle NJ. Amphiregulin Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Study of 93 Cases. *Prostate.* 2004 Feb; 1:58(2):164–8.
381. ***Bostwick DG***, Qian J, Civantos F, Roehrborn CG, Montironi R. Does Finasteride Alter the Pathology of the Prostate and Cancer Grading? *Clin. Pros. Can.* 2004 Mar; 2(4):228–35. Review.
382. ***Bostwick DG***, Qian J. High-Grade Prostatic Intraepithelial Neoplasia. *Mod. Pathol.* 2004 Mar; 17(3):360–79.
383. ***Bostwick DG***, Liu L, Qian J. PIN and ASAP: Recognizing the Predictors of Prostate Cancer. *Cont. Urol.* 2004 Jun; 16(6):12–22.
384. ***Bostwick DG***, Lui L, Qian J. PIN and ASAP. *Cont. Urol.* 2004 Jun; 16(6):12–22.
385. ***Bostwick DG***, Bostwick KC. Vanishing Prostate Cancer in Radical Prostatectomy Specimens: Incidence and Long Term Follow-up in 38 Cases. *BJU Int.* 2004 Jul; 94(1):57–8.

386. Montironi R, Thompson D, Scarpelli M, Mazzucchelli R, Peketi P, Hamilton PW, ***Bostwick DG***, Bartels PH. Karyometry Detects Subvisual Differences in Chromatin Organization State between Cribriform and Flat High-Grade Prostatic Intraepithelial Neoplasia. *Mod. Pathol.* 2004 Aug; 17(9):928–37.
387. ***Bostwick DG***, Hossain D, Qian J, Neumann RM, Yang P, Young RH, di Sant'agnese PA, Jones EC. Phyllodes Tumor of the Prostate: Long-Term Follow-up Study of 23 Cases. *J. Urol.* 2004 Sept; 172(3):894–99.
388. McCarthy RP, S, ***Bostwick DG***, Qian J, Eble JN, Wang M, Lin H, Cheng L. Molecular Genetic Evidence for Different Clonal Origins of Epithelial and Stromal Components of Phyllodes Tumor of the Prostate. *Am. J. Pathol.* 2004 Oct; 165(4):1395–400.
389. Marks LS, Kojima M, Demarzo A, Heber D, ***Bostwick DG***, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW. Prostate Cancer in Native Japanese and Japanese-American Men: Effects of Dietary Differences on Prostatic Tissue. *Urology.* 2004 Oct; 64(4):765–71.
390. Sinha AA, Quast BJ, Reddy PK, Lall V, Wilson MJ, Qian J, ***Bostwick DG***. Microvessel Density as a Molecular Marker for Identifying High-Grade Prostatic Intraepithelial Neoplasia Precursors to Prostate Cancer. *Exp. Mol. Pathol.* 2004 Oct; 77(2):153–59.
391. ***Bostwick DG***, Burke HB, Djzkiew D, Euling S, Ho S, Landolph J, Morrison H, Sonawame R, Shifflett T, Waters DJ, Timms B. Human Prostate Cancer Risk Factors. *Cancer.* 2004 Nov; 15;101(10 Suppl):2371–490. Review.
392. Chong KT, Hampson NB, ***Bostwick DG***, Vessella RL, Corman JM. Hyperbaric Oxygen does not Accelerate Latent In Vivo Prostate Cancer: Implications for the Treatment of Radiation-Induced Hemorrhagic Cystitis. *BJU Int.* 2004 Dec; 94(9):1275–78.
393. Christian J, Lamm TC, Morrow JF, ***Bostwick DG***. Corpora Amylacea in Adenocarcinoma of the Prostate: Histology within Needle Core Biopsies. *Mod. Pathol.* 2005 Jan; 18(1):36–39.
394. Iczkowski KA, Qian J, Somerville MC, Rittmaster RS, Andriole GL, ***Bostwick DG***. The Dual 5-Alpha-Reductase Inhibitor Dutasteride Induces Atrophic Changes and Decreases Relative Cancer Volume in Human Prostate. *Urology.* 2005 Jan; 65(1):76–82.
395. Montironi R, Mazzucchelli R, Stramazzotti D, Scarpelli M, Lopez-Beltran A, ***Bostwick DG***. Basal Cell Hyperplasia and Basal Cell Carcinoma of the Prostate: A Comprehensive Review and Discussion of a Case with C-erbB-2 Expression. *J. Clin. Pathol.* 2005 Mar; 58(3):290–96.
396. Lopez-Beltran A, Qian J, Montironi R, Luque RJ, ***Bostwick DG***. Atypical Adenomatous Hyperplasia (Adenosis) of the Prostate: DNA Ploidy Analysis and Immunophenotype. *Int. J. Surg. Pathol.* 2005 Apr; 13(2):167–73.
397. ***Bostwick DG***. Prostate Cancer Guide: Part 1: Prevention. *Bottom Line Health.* 2005 May; 19(5):5–7.
398. Lopez-Beltran A, Elbe JN, ***Bostwick DG***. Pleomorphic Giant Cell Carcinoma of the Prostate. *Arch. Pathol. Lab Med.* 2005 May; 129(5):683–85.

399. ***Bostwick DG***, Adolfsson J, Burke HB, Damber JE, Huland H, Pavone-Maculoso M, Waters DJ. Epidemiology and Statistical Methods in Prediction of Patient Outcome. *Scand. J. Urol. Nephrol.* (Suppl). 2005 May; (216):94–110.
400. MacLennan GT, ***Bostwick DG***. Tubulocystic Carcinoma, Mucinous Tubular and Spindle Cell Carcinoma, and Other Recently Described Rare Renal Tumors. *Clin. Lab Med.* 2005 Jun; 25(2):393–416.
401. MacLennan G, Cheng L, ***Bostwick DG***. Renal Neoplasms: An Ever-changing Landscape. *Clin. Lab Med.* 2005 Jun; 25(2).
402. Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Beltran AL, ***Bostwick DG***. Incidentally Detected Prostate Cancer in Cystoprostatectomies: Pathological and Morphometric Comparison with Clinically Detected Cancer in Totally Embedded Specimens. *Hum Pathol.* 2005 Jun; 36(6):646–54.
403. Waters DJ, Shen S, Glickman LT, Cooley DM, ***Bostwick DG***. Prostate Cancer Risk and DNA Damage: Translational Significance of Selenium Supplementation in a Canine Model. *Carcinogenesis.* 2005 Jul; 26(7):1256–62.
404. Burke HB, ***Bostwick DG***, Meiers I, Montironi R. Prostate Cancer Outcome: Epidemiology and Biostatistics. *Anal. Quant. Cytol. Histol.* 2005 Aug; 27(4):211–7. Review.
405. Schlesinger C, ***Bostwick DG***, Iczkowski KA. High-Grade Prostatic Intraepithelial Neoplasia and Atypical Small Acinar Proliferation: Predictive Value for Cancer in Current Practice. *Am J Surg Pathol.* 2005 Sept; 29(9):1201–1207.
406. Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, Qian J, ***Bostwick DG***. Performance of Urine Test in Patients Monitored for Recurrence of Bladder Cancer: A Multicenter Study in the United States. *J. Urol.* 2005 Oct; 174(4 Pt 1):1238–41.
407. ***Bostwick DG***, Meiers I. Prostate Biopsy and Optimization of Cancer Yield. *Eur. Urol.* 2006 Mar; 49(3):415–17.
408. Melissari M, Lopez-Beltran A, Mazzucchelli R, Froio E, ***Bostwick DG***, Montironi R. High Grade Prostatic Intraepithelial Neoplasia with Squamous Differentiation. *J. Clin. Path.* 2006 Apr; 59(4):437–39.
409. ***Bostwick DG***, Meiers I. Atypical Small Acinar Proliferation (ASAP): Clinical Significance in 2006. *Archives of Pathology and Laboratory Medicine.* 2006 Jul; 130(7):952–57.
410. ***Bostwick DG***, Gould VE, Qian J, Susani M, Marberger M. Prostate Cancer Detected by uPM3: Radical Prostatectomy Findings. *Mod. Pathol.* 2006 May; 19(5):630–33.
411. Alberts SR, Novotny PJ, Sloan JA, Danella J, ***Bostwick DG***, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinz CL. Flutamide in Men with Prostatic Intraepithelial Neoplasia: A Randomized, Placebo-Controlled Chemoprevention Trial. *Am. J. Ther.* 2006 Jul–Aug; 13(4):291–97.
412. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D, ***Bostwick DG***, Steiner, M. Toremifene for the Prevention of Prostate Cancer in Men with High Grade Prostatic Intraepithelial Neoplasia: Results of a Double-Blind, Placebo Controlled, Phase IIB Clinical Trial. *J. Urol.* 2006 Sept; 176:965–71.

413. Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, ***Bostwick DG***, Montorsi F. Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies (Also Referred to as “Atypical Small Acinar Proliferation Suspicious for but not Diagnostic of Malignancy”). Eur. Urol. 2006 Oct; 50(4):666–74.
414. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JL, Veltri RW, Makarov DV, Partin AW, ***Bostwick DG***, Macairan ML, Nelson, PS. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men with Late-onset Hypogonadism: A Randomized Controlled Trial. JAMA. 2006 Nov; 15; 296(19):2351–61.
415. ***Bostwick DG***, Liu L, Brawer, MK. High-Grade Prostatic Intraepithelial Neoplasia. Rev. Urol. 2006 Fall; 6(4) 171–79.
416. Wang X, Jones TD, Zhang S, Eble JN, ***Bostwick DG***, Qian J, Lopez-Beltran A, Montironi R, Harris JJ, Cheng L. Amplifications of EGFR Gene and Protein Expression of EGFR, Her-2/neu, c-kit, and Androgen Receptor in Phyllodes Tumor of the Prostate. Mod. Pathol. 2007 Feb; 20(2):175–82.
417. ***Bostwick DG***, Meiers I. Diagnosis of Prostatic Carcinoma after Therapy. Archives of Pathology & Laboratory Medicine. 2007 Mar; 131(3):360–71.
418. Meiers I, Shanks JH, ***Bostwick DG***. Glutathione S-transferase pi (GSTP1) Hypermethylation in Prostate Cancer: Review 2007. Pathology, 2007 Jun; 39(3):299–304.
419. Liu L, Qian J, Singh H, Meiers I, Zhou X, ***Bostwick DG***. Immunohistochemical Analysis of Chromophobe Renal Cell Carcinoma, Renal Oncocytoma, and Clear Cell Carcinoma: An Optimal and Practical Panel for Differential Diagnosis. Archives of Pathology and Lab Medicine. 2007 Aug; 131(8):1290–1297.
420. ***Bostwick DG***, Meiers I, Hossain D. Phyllodes Tumor of the Prostate: Current Concepts and Update on Classification of Prostatic Soft Tissue Tumors. Path. Case Reviews. 2007 Jul/Aug; 12(4):1–6.
421. Venkataraman G, Heinze G, Holmes EW, Ananthanarayanan V, ***Bostwick DG***, Paner GP, Bradford-De La Garza CM, Brown HG, Flanigan RC, Wojcik EM. Identification of patients with low-risk for aneuploidy: Comparative discriminatory models using linear and machine-learning classifiers in prostate cancer. Prostate, 2007 Aug 7; 67(14):1524–1536.
422. ***Bostwick DG***, Meiers I, Shanks, JH. Glutathione S-transferase: Differential Expression of Alpha, Mu, and Pi Isoenzymes in Benign Prostate, Prostatic Intraepithelial Neoplasia, and Prostatic Adenocarcinoma. Hum Path. 2007 Sept 38, 1394–1401.
423. Nickel JC, Roehrborn CG, O’Leary MP, ***Bostwick DG***, Somerville MC, Rittmaster RS. Examination of the Relationship Between Symptoms of Prostatitis and Histological Inflammation: Baseline Data From the REDUCE Chemoprevention Trial. J. Urol. 2007 Sept; 178(3):896–901.
424. Waters DJ, Shen S, Xu H, Kenggeri SS, Cooley DM, Chiang EC, Chen Y, Schlittler D, Oteham C, Combs GF Jr, Glickman LT, Morris JS, ***Bostwick DG***. Noninvasive Prediction of Prostatic DNA Damage by Oxidative Stress

- Challenge of Peripheral Blood Lymphocytes. Cancer Epidemiol Biomarkers Prev. 2007 Sept; 16(9): 1906–10.
425. Meiers I, Singh H, Hossain D, Lang K, Liu L, Qian J, Verhest AP, **Bostwick DG**. Improved Filter Method for Urine Sediment Detection of Urothelial Carcinoma by Fluorescence in Situ Hybridization. Archives of Pathology and Lab Medicine. 2007 Oct; 131(10): 1574–7.
426. Nickel JC, Roehrborn CG, O’Leary MP, **Bostwick DG**, Somerville MC, Rittmaster RS. The Relationship Between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial. Eur. Urol. 2007 Nov 20 *In Print*.
427. **Bostwick DG**, Ma J. Over-Diagnosis of High-Grade Prostatic Intraepithelial neoplasia: A Prospective Study of 251 Cases. BJU Int. 2007 Nov; 100(5): 1036–9.
428. **Bostwick DG**, Waters DJ, Farley ER, Meiers I, Rukstalis D, Cavanaugh WA, Ragde H, Dineen MK, Bahn D, Scionti S, Babian R, Ellis DS, Rewcastle JC, Burke HB, Andriole GL, Onik G, Aarqawi AE, Maksem J, Barzell WE. Group Consensus Reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urol. 2007 Dec; 70(6) Suppl): 43–44.
429. Meiers I, Waters DJ, **Bostwick DG**. Preoperative Prediction of Multifocal Prostate Cancer and Application of Focal Therapy: Review 2007. Urol. 2007 Dec; 70(6 Suppl): 3–8.
430. Andriole GL, Bullock TL, Belani JS, Traxel E, Yan Y, **Bostwick DG**, Humphrey PA. Is There A Better Way to Biopsy the Prostate? Prospects for a Novel Transrectal Systematic Biopsy Approach. Urol. 2007 Dec; 70(6 Suppl): 22–26.
431. Iczkowski KA, Hossain D, Torkko KC, Qian J, Lucia MS, Wheeler TM, Rewcastle JC, **Bostwick DG**. Preoperative Prediction of Unifocal, Unilateral, Margin-Negative, and Small Volume Prostate Cancer. Urol. 2008 Jun; 71(6): 1166–71.
432. Childs L, Hull D, **Bostwick DG**. Adult Urinary Bladder Rhabdomyosarcoma. Urol. 2008 Apr 7 *In Print*.
433. Waters DJ, Chiang EC, **Bostwick DG**. The Art of Casting Nets: Fishing for the Prize of Personalized Cancer Prevention. Nutr. Cancer. 2008 Jan-Feb; 60(1): 1–6.
434. Hull D, **Bostwick DG**. Androgen Deprivation Therapy for Precancerous Lesions of the Prostate. Best Pract. Res. Clin. Endocrinol Metab. 2008 Apr; 22(2) 285–91.
435. **Bostwick DG**. Guest Editor, Contemporary Urologic Pathology: Difficult and Common Diagnostic Issues. Pathology Case Reviews. 2008 Jul/Aug; 13(4) 125–153.
436. **Bostwick DG**. Problems in Prostate and Bladder Pathology. Pathology Case Reviews. 2008 Jul/Aug; 13(4) 123–124.
437. Meiers I, Kahane H, **Bostwick DG**. Atypical Small Acinar Proliferation in the Prostate. Pathology Case Reviews. 2008 Jul/Aug; 13(4) 129–134.
438. Marks LS, **Bostwick DG**. Prostate Cancer Specificity of PCA3 Gene Testing:

- Examples from Clinical Practice. Rev. Urology 2008 Summer; 10(3): 175–81.
439. Evans AJ, Henry PC, Van der Kwast TH, Tkachuk DC, Watson D, Lockwood GA, Fleshner NE, Cheung C, Belander EC, Amin MB, Boccon-Gibod L, **Bostwick DG**, Egevad L, Epstein JL, Grignon DJ, Jones EC, Montironi R, Moussa M, Sweet JM, Trpkov K, Wheeler TM, Srigley JR. Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens. Am J Surg. Path. 2008 *In Print*.
440. Hossain D, Meiers I, Qian J, MacLennan GT, **Bostwick DG**. Prostatic Leiomyoma with Atypia: Follow-up Study of 10 Cases. Annals of Diag. Path. 2008 Oct; 12(5): 328–32.
441. Cheng L, **Bostwick DG**. Over-diagnosis of Bladder Carcinoma. Annals Quant. Cytol. Histol. 2008 Oct; 30(5): 261–4.
442. Hossain D, Meiers I, Qian J, MacLennan GT, **Bostwick DG**. Prostatic Stromal Hyperplasia With Atypia: Follow-up Study of 18 Cases. Arch. Pathol. Lab Med. 2008 Nov; 132(11): 1729–33.
443. Hull D, Ma J, Singh H, Hossain D, **Bostwick DG**. Precursor of Prostate-Specific Antigen Expression in Prostatic Intraepithelial Neoplasia. BJU Int'l. 2009 Apr 17. *In Print*.
444. Onik G, Miessau M, **Bostwick DG**. Three-Dimensional Prostate Mapping Biopsy Has A Potentially Significant Impact on Prostate Cancer Management. J. Clin. Oncol. 2009 Sept 10; 27(26): 4321–6.
445. Legette LL, Martin BR, Shahnazari M, Lee WH, Helferich WG, Qian J, Waters DJ, Arabshahi A, Barnes S, Welch J, **Bostwick DG**. Supplemental Dietary Racemic Equol Has Modest Benefits to Bone but Has Mild Uterotropic Activity in Ovariectomized Rats. J. Nutr. 2009 Oct; 139(10): 1908–13.
446. **Bostwick DG**, Qian J, Drewnowska K, Varvel S, Bostwick KC, Marberger M, Rittmaster RS. Prostate Needle Biopsy Quality in Reduction by Dutasteride of Prostate Cancer Events Study: Worldwide Comparison of Improvement with Investigator Training and Centralized Laboratory Processing. Urol. 2010; Jun; 75(6): 1406–10.
447. Van Der Kwast, TH, Evans A, Lockwood G, Tkachuk D, **Bostwick DG**, Epstein JI, Humphrey PA, Montironi R, Van Leeenders GJ, Pihl CG, Neetens I, Kujala PM, Laurila M, Mazerolies C, Bubendorf L, Finelli A, Watson K, Srigley J. Variability in Diagnostic Opinion Among Pathologists for Single Small Atypical Foci in Prostate Biopsies. Amer. J. Surg. Path. 2010; *In Print*.
448. Chiang E, Shen S, Kengeri SS, Zu H, Combs GF, Morris JS, **Bostwick DG**, Waters DJ. Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-shaped Relationship Between Selenium Status, DNA Damage, and Apoptosis. Int'l Dose Response Soc. 2009; *In Print*.
449. Qian J, Weber D, Cochran R, Hossain D, **Bostwick DG**. Detection of Chromosomal Anomalies in Endometrial Atypical Hyperplasia and Carcinoma by Using Fluorescence In Site Hybridization. Cancer Cytopathol. 2010 Mar 11; *In print*.
450. Cheng L, **Bostwick DG**. Atypical Sclerosing Adenosis of the Prostate: A Rare Mimic of Adenocarcinoma. Histopath. 2010 56; 627–631.

451. Andriole GL, ***Bostwick DG***, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela T, Teloken C, Tindall DJ, Somerville C, Wilson TH, Fowler IL, Rittmaster RS. Effect of Dutasteride on the Risk of Prostate Cancer. *New England J. Med.* 2010 Apr1; 362:1192–1202.
452. Qian J, ***Bostwick DG***, Iczkowski KA, Betre K, Wilson MJ, Le C, Sinha AA. Characterization of Prostate Cancer in Needle Biopsy by Cathepsin B, Cell Proliferation and DNA Ploidy. *Anticancer Res.* 2010 Mar; 30(3):719-25.
453. Mouraviev V, Villiers A, ***Bostwick DG***, Wheeler TM, Montironi R, Polascik TJ. Understanding the Pathological Features of Focality, Grade and Tumor Volume of Early-stage Prostate Cancer as a Foundation for Parenchyma-sparing Prostate Cancer Therapies: Active Surveillance and Focal Targeted Therapy. *BJUI Int'l.* 2011 April 13; 1-12.
454. Marberger M, McConnell JD, Fowler I, Andriole GL, ***Bostwick DG***, Somerville MC, Rittmaster RS. Biopsy Misidentification Identified by DNA Profiling in a Large Multicenter Trial. *J. Clin. Oncol.* 2011 May 1:29(13):1744-9.
455. Qian J, Hossain D, Adupe J, Drewnowska K, ***Bostwick, DG***. Differentiation of Melanoma and Benign Nevi by Fluorescence *in situ* Hybridization (MelanoFISH). *Melanoma Research.* 2011 Oct 21(5):426-30.
456. ***Bostwick DG***. Words of Wisdom: Re: Biopsy Misidentification Identified by DNA Profiling in a Large Multicenter Trial. *Eur.Urol.* 2011 August: 60(2)396.
457. Mouraviev V, Villiers A, ***Bostwick DG***, Wheeler TM, Montironi R, Polascik TJ. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. *BJU Int.* 2011 Oct; 108(7): 1074-85.
458. Marberger M, McConnell JD, Fowler I, Andriole GL, ***Bostwick DG***, Somerville MC, Rittmaster RS. Biopsy misidentification identified by DNA profiling in a large multicenter trial. *J Clin Oncol.* 2011 May 1:29(13):1744-9.
459. ***Bostwick DG***, Cheng L. Precursors of Prostate Cancer. *Histopath.* 2012 Jan; 60(1):4-27.
460. Cheng L, Montironi R, ***Bostwick DG***, Lopez-Beltran A, Berney DM. *Histopathology.* 2012 Jan: 60(1):87-117.
461. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Glover WL Jr, ***Bostwick, DG***. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. *J. Urol.* 2012 Nov: 118(5):1726-31.
462. Waters DJ, Shen S, Kengeri SS, Chiang EC, Combs GF, Combs GF Jr, Morris JS, ***Bostwick DG***. Prostatic response to supranutritional selenium supplementation: comparison of the target tissue potency of selenomethionine vs. selenium-yeast on markers of prostatic homeostasis. *Nutrients.* 2012 Nov 6;4(11): 1650-63.
463. Hossain D, ***Bostwick, DG***. Significance of the TMPRESS2:ERG gene fusion in prostate cancer. *BJU Int.* 2013 May:111(5):834-5.



464. Chiang EC, **Bostwick DG**, Waters DJ. Homeostatic housecleaning effect of selenium: Evidence that noncytotoxic oxidant-induced damage sensitizes prostate cancer cells to organic selenium-triggered apoptosis. *Biofactors*: 2013 Apr 29. 10:1002/biof.1106
465. **Bostwick, DG**, Kahane H. Adequate histologic sectioning of prostate needle biopsies. *Ann Diagn Pathol*. 2013 Aug; 17(4):357-60.
466. **Bostwick, DG**, Radiofrequency identification specimen tracking in anatomical pathology: pilot study of 1067 consecutive prostate biopsies. *Ann Diagn Pathol*. 2013, Oct. 17; (5):391-402.
467. Hossain D, Hull D, Kalantarpour F, Maitlen R, Qian J. **Bostwick, DG**. Does polymavirus infection interfere with bladder cancer fluorescence in situ hybridization? *Diagn Cytopathol*. 2013 Sept 5. doi. 10:1002/dc.23027.
468. Iczkowski KA, Torkko KC, Wilson RS, Lucia MS, **Bostwick DG**. Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides. *Hum Pathol*. 2014 Jan;45(1):4-8.
469. Lucia MS, **Bostwick DG**, Somerville MC, Fowler IL, Rittmaster RS. Arch Pathol Lab Med. 2013 Dec: 137(12):1740-6. Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason Grading Using Needle Biopsies From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
470. Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, **Bostwick DG**, Steiner MD, Rubin MA. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. *J Clin Oncol*. 2014 Jan 20;32(3):206-11 [Epub 2013 Dec 2].
471. Bhat ZY, **Bostwick DG**, Hossain D, Zeng X. Participation of Functionally Active Plasma Cells in Acute Rejection and Response to therapy in Renal Allografts. *DNA Cell Biol*. 2014 Mar 31.
472. **Bostwick DG**, Hossain D. Does subdivision of the “atypical” urine cytology increase predictive accuracy for urothelial carcinoma? *Diagn Cytopathol*. 2014 May 17.
473. Chen LN, Rubin RS, Othepa E, Cer C, Yun E, Agarwal RP, Collins BT, McGeagh K, Pahira J, Bandi G, Kowalczyk K, Kumar D, Dritschilo A, Collins SP, **Bostwick DG**, Lynch JH, Suy S. correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies. *Prostate*. 2014 May; 74(7):714-21.
474. Andriole GL, **Bostwick DG**, Gomella LG, Marberger M, Montorsi F, Tammela TL, Tindall DJ, Fowler IL, Garges HP, Wilson TH, Castro R. Modeling and Analysis of Gleason Score 8-10 Prostate Cancers in the REDUCE Study. *Urology*, 2014 Aug; 84(2):393-9.
475. **Bostwick DG**, Day CE, Meiers I. Optimizing prostate specimen handling for diagnosis and prognosis. *Methods Mol Biol*. 2014; 1180:337-52.
476. Isabelle Meiers, MD, and **David G. Boswick**, MD, MBA; Prostate Cancer: Optimal Tissue Processing for Diagnosis and Prognosis. Pathology Case Reviews. Volume 19, Number 3, May/June 2014 ISSN 1082-9784; Page 118

477. Deloar Hossain, MD, and ***David G. Bostwick***, MD, MBA; Immunohistochemical Biomarkers of Prostatic Carcinoma. Pathology Case Reviews. Volume 19, Number 3, May/June 2014 ISSN 1082-9784; Page 136
478. Kenneth A. Iczkowski, MD and ***David G. Bostwick***, MD, MBA; Atypical Small Acinar Proliferation of the Prostate: 16 Years' Experience; Pathology Case Reviews. Volume 19, Number 3, May/June 2014 ISSN 1082-9784; Page 147.
479. Hillel Kahane, MD and David G. Bostwick, MD, MBA; Florid Basal Cell Hyperplasia and Other Benign Mimics of Prostate Cancer; Pathology Case Reviews. Volume 19, Number 3, May/June 2014 ISSN 1082-9784; Page 154.
480. Jun Ma, MD and David G. Bostwick, MD, MBA; High-Grade Prostatic Intraepithelial Neoplasia and Intraductal Carcinoma with Intraluminal small Cell Features; Pathology Case Reviews. Volume 19, Number 3, May/June 2014 ISSN 1082-9784; Page 163

### **Books**

1. ***Bostwick DG*** and Rosenbloom AJ. Official Bicycling Guide to Maryland, Baltimore News American, Baltimore, MD, 1976; endorsed by the Maryland Commission on Physical Fitness and the Maryland State Department of Tourism.
2. ***Bostwick DG***. Microwave Oven Methods in Pathology, Stat. Path. Press, Riderwood, MD, 1987.
3. ***Bostwick DG***. Ed. Pathology of the Prostate, Churchill Livingstone, New York, NY, 1990.
4. ***Bostwick DG***, Eble J. Eds. Urologic Surgical Pathology, Mosby-Year Book Publishers, Inc., St. Louis, MO, 1997.
5. ***Bostwick DG***, Eble J. Eds. Urologic Surgical Pathology, Mosby-Year Book Publishers, Inc., St. Louis, MO, *Second Edition*, 2008.
6. ***Bostwick DG***, Dundore PA. Prostate Biopsy Interpretation. Chapman-Hall Publishers, Inc., London, England, 1997.
7. Foster CS, ***Bostwick DG***. Eds. Pathology of the Prostate, W.B. Saunders, Philadelphia, PA, 1998.
8. ***Bostwick DG***, MacLennan GM, Larson TA. The American Cancer Society Guide to Prostate Cancer. Villiard Press (Random House), New York, NY, 1996; *Second Edition*, 1999.
9. ***Bostwick DG***, Lopez-Beltran A. Bladder Biopsy Interpretation. United Pathologists Press, Riderwood, MD, 1999.

10. Cheng L, **Bostwick DG**. Essentials of Diagnostic Pathology, Humana Press, Totowa, NJ, 2002.
11. MacLennan G, Resnick M, **Bostwick DG**. Pathology for Urologists. W.B. Saunders, Philadelphia, PA, 2003.
12. **Bostwick DG**, Crawford ED, Higano CS, Roach M. Eds. American Cancer Society's Complete Guide to Prostate Cancer, American Cancer Society, Atlanta, GA, 2005.
13. Cheng L, **Bostwick DG**. Essentials of Anatomic Pathology, 2<sup>nd</sup> Ed. Humana Press, Totowa, NJ, 2007. *Third Edition* 2011
14. **Bostwick DG**, Morrow JF, Cheng L, Qian J, Montironi R, Lopez-Beltran A. Bladder Biopsy Interpretation. Springer-Verlag 2007.
15. Cheng L, **Bostwick DG**. Essentials of Anatomic Pathology, 3<sup>rd</sup> Ed. *May 2010*.
16. Cheng, L, Lopez-Beltran,A.,**Bostwick DG**. Bladder Pathology. Wiley-Blackwell 2012.
17. Cheng L, **Bostwick DG**, Urologic Surgical Pathology, Elsevier Saunders, Philadelphia, PA *Third Edition* 2013.

### **Book Chapters**

1. **Bostwick DG**. Origins of Prostatic Carcinoma. In: Progress in Reproductive and Urinary Tract Pathology, Vol. I, Eds. Damjanov I. Cohen AH, Mills SE, and Young RH. Field and Wood, New York, NY, 1989.
2. Mills SE, **Bostwick DG**, Murphy W, and Weiss M. Symposium on Pathology of the Prostate. In: Pathology Annual, Eds. Fechner RE and Rosen PP. Williams and Wilkens, Baltimore, MD, 1990.
3. **Bostwick DG** and Choi C. Prognostic Factors in Prostate Cancer. In: Urology Annual, Ed. S. Rous, Norton Medical Books, Philadelphia, PA 1992.
4. Murphy GP, Oesterling JE, Algaba F, Bodrogi I, **Bostwick DG**, et al. Prostate Specific Antigen: Pertinent Issues for Distinguished Prostate Cancer from Benign Prostatic Hyperplasia. In: Proceedings – The International Consultation on Benign Prostatic Hyperplasia. Ed. Cockett ATK et al., Scientific Communication International, 1993; pp. 229–252.

5. Mostofi FK, Sesterhenn IA, Algaba F, **Bostwick DG**. Pathology of Benign Enlargement of the Prostate. In: Proceedings – The International Consultation on Benign Prostatic Hyperplasia. Ed. Cockett ATK et al., Scientific Communication International, 1993; pp. 515–537.
6. **Bostwick DG**. Significance of Tumor Volume in Prostate Cancer. In: Urology Annual, Ed. S. Rous, Norton Medical Books, Philadelphia, PA, 1994; pp. 1–22.
7. **Bostwick DG**, Amin MB. Pathology of the Prostate and Seminal Vesicles. In: Anderson's Textbook of Pathology, Eds. Damjanov I, Lindner J. Mosby. Year Book Publishers, Inc., St. Louis, MO, 1995.
8. **Bostwick DG**. Prostatic Intraepithelial Neoplasia. In: Comprehensive Textbook of Genitourinary Oncology, Eds. Vogelzang NJ, Scardino PT, Shipley WS, Coffey DS. Williams and Wilkins, Baltimore, MD, 1995; pp. 639–645.
9. **Bostwick DG** (Pathology Editor), Stedman's Medical Dictionary, 26th Edition, Williams and Wilkins, Baltimore, MD, 1995.
10. **Bostwick DG**. Atypical Adenomatous Hyperplasia of the Prostate. In: Advances in Pathology and Laboratory Medicine. Eds. Weinstein RS, Graham AR. Mosby-Year Book, Inc. Chicago, IL, 1996; pp. 191–207.
11. **Bostwick DG**. Is the Behavior of Prostate Cancer Understood? In: Questions and Uncertainties about Prostate Cancer. Ed. Peeling WB. Blackwell Science, Cambridge, MA, 1996; pp. 30–49.
12. **Bostwick DG**. Pathology of Benign Prostatic Hyperplasia. In: Textbook of Benign Prostatic Hyperplasia. Eds. Kirby R, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. ISIS Medical Media, Oxford, UK, 1996; pp. 91–104.
13. **Bostwick DG**, Oesterling JE. The Urologic and Male Reproductive Systems. In: Pathology for the Surgeon. Eds. Banks PM, Kraybill WG. W.B. Saunders Company, Philadelphia, PA, 1996; pp. 217–233.
14. **Bostwick DG**. Pathology of Prostate Cancer. In: Urologic Cancer, Blackwell Science, Cambridge, MA, 1997; pp. 15–47.
15. **Bostwick DG**, MacLennan GT. Prostate-Specific Antigen in Diagnostic Pathology of Prostate Cancer. In: Urology Annual, W.W. Norton & Company, New York, NY, 1997.
16. **Bostwick DG**. Pathology of Prostate Cancer. In: International Handbook of Prostate Cancer. Ed. David Kirk, Euromed Communications, Surrey, UK, 1999; pp. 13–42.

17. **Bostwick DG**. Pathology Ed., Stedman's Medical Dictionary, 27<sup>th</sup> Edition. Williams and Wilkens, Baltimore, MD, 2000.
18. **Bostwick DG**. Prostatic Intraepithelial Neoplasia. In: Comprehensive Textbook of Genitourinary Oncology. Eds. Vogelzang NJ, Scardino PT, Shipley WS, Coffey DS. Lippincott Williams and Wilkins, Philadelphia, PA, 2000; pp. 604–611.
19. **Bostwick DG**. The Pathology of Benign Prostatic Hyperplasia. In: Textbook of Benign Prostatic Hyperplasia, 2<sup>nd</sup> Edition. Eds. Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Taylor & Francis, London, UK, 2005; pp. 97–111.
20. **Bostwick DG**. Immunohistology of the Prostate, Bladder, Testis and Kidney. In: Diagnostic Immunohistochemistry, 2<sup>nd</sup> Edition. Ed. Dabbs DJ, Churchill Livingstone, Elsevier, St.Louis, MO, 2006; pp. 509–610.
21. **Bostwick DG**, Montironi R, Qian J, Lopez-Beltran A, Cheng L. Urothelial Bladder Tumor Pathology: Contemporary Consensus Classification and Diagnosis Based on the World Health Organization (WHO) 1973 Classification. In: Textbook of Bladder Cancer. Eds. Lerner SP, Schoenberg, MP, Sternberg, CN, Taylor & Francis, Oxford, UK, 2006; pp. 71–84.
22. Algaba F, **Bostwick DG**, Isaacs J, Shiraishi T, Umbas R, Watson B. New Developments in the Pathobiology of Prostate Disease. In: Prostate Cancer, (First Part) Edition 2006. Eds. McConnell J, Denis L, Akaza, H, Khoury S, Schalken J, Editions 21, Paris, France, 2006; pp. 67–84.
23. Meiers, I, **Bostwick DG**. Histopathological Markers and Precursor Lesions. In: Therapeutic Strategies in Prostate Cancer. Eds. Feneley, M R, Payne, HA, Biddles Ltd, King's Lynn, Norfolk, UK, 2007; pp. 43–66.
24. **Bostwick DG**, Meiers, I. Pathology of Prostate Cancer. In: International Handbook of Prostate Cancer, 3<sup>rd</sup> ed. Ed. Kirk, D, Euromed Communications, Ltd., Haslemere, Surrey, UK, 2008; pp. 15–49.
25. **Bostwick DG**, Meiers, I. Urinary Tract and Male Genital System: Prostate. In: Modern Surgical Pathology. Eds. Weidner N, Cote R, Suster S, Weiss LM, El Sevier Philadelphia, PA 2009; pp. 1121-1180.
26. **Bostwick DG**; Molecular Biology of Prostate Cancer: Practical Considerations for Diagnosis and Prognosis Aug 2013, 31970\_ch30\_001-019.indd.
27. Thomas J. Polascik, Arnauld Villers, Thomas M. Wheeler, **DG Bostwick**, Rodolfo Montironi, Pierre Nevoux, and Vladimir Mouraviev. Imaging and

Focal Therapy of Early Prostate Cancer/Pathologic Basis for Focal Therapy: Understanding Cancer Grade, Volume and Spatial Location. pp. 53-71.

28. J. Stephen Jones, ***DG Bostwick***, Prostate Cancer Diagnosis, PSA, Biopsy and Beyond. Pathological Implications of Prostate Biopsy. pp 189-225, 2013.
29. Christina E. Day, ***DG Bostwick***, Isabelle Meiers, Histopathology Methods and Protocols, pp 337-352, 2014.

### Abstracts and Letters

1. ***Bostwick DG***, Bose D, Srigley J, Grignon, Maksem J, and Young R. Morphologic Criteria for Distinguishing Atypical Adenomatous Hyperplasia (Adenosis) from Well Differentiated Adenocarcinoma of the Prostate. Lab Invest 1991 (Eightieth Annual Meeting of the US and Canadian Academy of Pathology.)
2. ***Bostwick DG***, Al-Annouf N, Choi C, Fazekas V, Jockle G, Gavel D, Vaughn E, Bruce V. Establishment of the Formalin-Free Surgical Pathology Laboratory. Lab Invest 1991 (Eightieth Annual Meeting of the US and Canadian Academy of Pathology.)
3. Weaver MG, Abdul-Karin FW, Srigley J, ***Bostwick DG***, Ro JY, and Ayala AG. Paneth Cell-Like Changes of Prostate: A Histological, Immunohistochemical, and Electron Microscopic Study. Lab Invest 1991 (Eightieth Annual Meeting of the US and Canadian Academy of Pathology.)
4. Doria M, Jin J, Wang H, Martinez R, Matthews J, and ***Bostwick DG***. Glycoconjugate Expression in Hyperplastic, Dysplastic, and Malignant Prostatic Epithelium. Lab Invest 1991 (Eightieth Annual Meeting of the US and Canadian Academy of Pathology).
5. ***Bostwick DG***, Jockle GA, and Fazekas VA. Patient-Initiated Laboratory Testing. JAMA 1991; 265:457.
6. ***Bostwick DG***, Graham SD, Napalkov P, Abrahamsson P, di Sant'Agnese PA, Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, Denis L, Schroeder F, Murphy GP. Staging of Early Prostate Cancer: A Proposed Tumor Volume-Based Prognostic Index. (Abstract). International Congress of the International Academy of Pathology, October 1992
7. ***Bostwick DG***, Srigley J, Grignon D, Maksem J, Humphrey P, van der Kwast T, Bose D, Young R. Atypical Adenomatous Hyperplasia (AAH) of the Prostate. International Congress of the International Academy of Pathology, October 1992.

8. ***Bostwick DG***, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural Patterns of High Grade Prostatic Intraepithelial Neoplasia. International Congress of the International Academy of Pathology, October 1992.
9. Devaraj LT, ***Bostwick DG***. Atypical Basal Cell Hyperplasia of the Prostate: Immunophenotypic Profile and Proposed Classification. International Congress of the International Academy of Pathology, October 1992.
10. ***Bostwick DG***, Larson T. Microwave Transurethral Thermal Therapy: Pathologic Findings in the Canine Prostate. Lab Invest 1993; 6:56A.
11. ***Bostwick DG***, Cupp MR, Oesterling JE. Tumor Volume in Prostate Cancer: Correlation of Needle Biopsy and Radical Prostatectomy. Lab Invest 1993; 6:57A.
12. ***Bostwick DG***, Dousa M, Crawford B. Neuroendocrine Differentiation in Prostatic Intraepithelial Neoplasia (PIN). Lab Invest 1993; 6:57A.
13. Meneses MF, ***Bostwick DG***, Kleer E, Kurtin PJ, Nascimento AG, Oesterling JE. Leiomyosarcoma of the Prostate. Lab Invest 1993; 6:64A.
14. Amin MB, ***Bostwick DG***, Kleer E, Kurtin PJ, Nascimento AG, Oesterling JE. Leiomyosarcoma of the Prostate. Lab Invest 1993; 6:64A.
15. Amin MB, Osborne B, Discigel G, ***Bostwick DG***. Malignant Lymphoma Involving the Prostate: Report of 52 Cases. Lab Invest 1993; 6:54A.
16. Salomao D, Graham S, ***Bostwick DG***. Vascular/Lymphatic Invasion in Prostate Cancer Correlates with Patterns of Progression. Lab Invest 1993; 6:54A.
17. Ellison E, Ferguson J, Zincke H, ***Bostwick DG***. "Nucleolus-Poor" Clear Cell Adenocarcinoma of the Prostate: A Distinctive Histologic Variant in Patients Receiving Total Androgen Blockade. Lab Invest 1993; 6:59A.
18. de la Roza G, Dundore P, ***Bostwick DG***. Intraepithelial Lymphocytes in the Normal Human Prostate. Lab Invest 1993; 6:58A.
19. Dundore P, Crawford B, ***Bostwick DG***. Type 4 Collagenase Expression in Prostatic Intraepithelial Neoplasia (PIN) and Adenocarcinoma. Lab Invest 1993; 6:58A.
20. ***Bostwick DG***, Larson T. Microwave Transurethral Thermal Therapy: Pathological Findings in the Canine Prostate. Annual Meeting, American Urological Association, San Antonio, TX, May 15–20, 1993.

21. Clinton SK, ***Bostwick DG***, Moore BJ, Gugger ET, Williams AS, and Erdman JW: Carotenoids are Found in the Human Prostate at Concentrations which Modulate Cellular Function In Vitro. FASEB, 1994.
22. Kletscher BA, Qian J, ***Bostwick DG***, Andrews PE, and Zincke H. Prospective Analysis of Multifocal Renal Cell Carcinoma: Influence of Histologic Pattern, Grade, Stage, Number, Volume and DNA Ploidy. (Abstract #994). Annual Meeting, American Urological Association, May 14–19, 1994.
23. Ferguson JK, ***Bostwick DG***, Suman, Zincke H, and Oesterling JE. PSA-Detected Prostate Cancers: Pathological Characteristics of Ultrasound Visible versus Ultrasound Invisible Tumors. (Abstract #1348) Annual Meeting, American Urological Association, May 14–19, 1994.
24. Bluestein DL, ***Bostwick DG***, Bergstralh E, and Oesterling JE: Eliminating the Need for Bilateral Pelvic Lymphadenectomy in Select Patients with Prostate Cancer. (Abstract #37) Annual Meeting, American Urological Association, May 14–19, 1994.
25. Blackwell K, ***Bostwick DG***, and Oesterling JE: Examination of Prostate Specific Antigen Levels in Prostate Cancer Patients Using PSA-Cancer Density: A New Concept to Improve PSA's Preoperative Prognostic Value. (Abstract #1202) Annual Meeting, American Urological Association, May 14–19, 1994.
26. Schneider BG, Pulitzer DR, Moehlmann RD, Prihoda TJ, ***Bostwick DG***, Saldivar V, Rodriguez-Martinez HA, Gutierrez-Diaz ME, O'Connell P. Microsatellite Instability and Loss of Heterozygosity in Gastric Cancer (Abstract) American Society of Human Genetics, 1994.
27. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, ***Bostwick DG***. Immuno-phenotype of Intraepithelial Neoplasia and Carcinoma of the Canine Prostate. American Association for Cancer Research, 1994.
28. ***Bostwick DG***. Early Prostate Cancer: A Pathologist's Perspective, Vol. 8. Minnesota Cancer Surveillance System. (Notes) Sept. 1994,
29. Larson T, ***Bostwick DG***, Corica A. Pathologic Comparison of Human Prostate between Treatment of Transurethral Laser versus Transurethral Microwave Thermal Therapy. 12th World Congress on Endourology and SWL 8th Annual Frontiers in Endourology 10th Basic Research Symposium. St. Louis, MO, Dec. 2–6, 1994.
30. Larson TR, Corica A, ***Bostwick DG***. Extent of Thermal Cell Death Correlated to Accurate Interstitial Temperatures of Ten Pathological Prostate Specimens Using Urologix T3 Microwave Transurethral Thermal Therapy Unit. 23rd



Congress of Societe Internationale D'Urologie, Sydney, Australia, Sept. 18–22, 1994.

31. Qian J, ***Bostwick DG***. The extent of high grade prostatic intraepithelial neoplasia in clinic localized prostatic adenocarcinoma. *Mod Pathol* 1994, 7:81A.
32. ***Bostwick, DG***, Qian J, Sinha AA, Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma retain a basement membrane. *Mod Pathol* 1994, 7:71A
33. Takahashi S, Qian J, Brown, J, ***Bostwick, DG***, Lieber MM and Jenkins RB. Potential markers of prostate cancer aggressiveness detected by fluorescent in situ hybridization in needle biopsies. *J Urol* 1994, 151:316A.
34. Davidson D, ***Bostwick, DG***, Qian J, Wollan P, Oesterling JE, Rudders F, Sirroky M, Stilmant M. Prostatic intraepithelial neoplasia is predictive of adenocarcinoma. *Mod Pathol* 1994, 7:72A.
35. Qian J, ***Bostwick, DG***. Extent and zonal localization of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: Relationship with adenocarcinoma in radical prostatectomy specimens. (Presented in *First International Consultation Meeting: Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma*. Ancona, Italy, September 1994.)
36. Allam CK, ***Bostwick DG***, Hayes JA, Upton MP, Wade GG, Domanowski GF, Klein MA, Boling EA, Stilmant MM. Interobserver Variability in the Diagnosis of High Grade Prostatic Intraepithelial Neoplasia and Adenocarcinoma. United States and Canadian Academy of Pathology (USCAP) Annual Pathology Meeting, Mod. Pathol. 1995, page 71A.
37. ***Bostwick DG***, Qian J, Frankel K. The Diagnosis of High Grade Prostatic Intraepithelial Neoplasia on Needle Biopsies. USCAP Annual Pathology Meeting, Mod. Pathol. 1995; page 73A.
38. ***Bostwick, DG***, Qian J, Frankel K. the diagnosis of prostatic intraepithelial neoplasia on needle biopsies. *Mod Pathol* 1995, 8:73A.
39. Cheville JC, ***Bostwick DG***. Post-Atrophic Hyperplasia of the Prostate, Histologic Features in 100 Whole-Mount Radical Prostatectomies. USCAP Annual Pathology Meeting, Mod. Pathol. 1995; page 74A.
40. Dundore PA, Nascimento AG, Cheville JC, ***Bostwick DG***. Carcinosarcoma of the Prostate. USCAP Annual Pathology Meeting, Mod. Pathol. 1995; page 75A.

41. Goldstein NS, Begin L, Grody WW, Novak JM, Qian J, **Bostwick DG**. Minimal or No Cancer in Radical Prostatectomy Specimens: Report of 13 Cases of the "Vanishing Cancer Phenomenon." USCAP Annual Pathology Meeting, #434, Mod. Pathol. 1995; page 76A.
42. Ferguson JF, Qian J, Husman DA, **Bostwick DG**. Increased androgen receptor expression is associated with survival in metastatic prostate cancer. *J Urol* 1995, 153:483A.
43. Qian J, Jenkins RB, Takahashi S, Lieber MM, **Bostwick DG**. Detection of Genetic Alterations in Prostatic Intraepithelial Neoplasia by Fluorescence In Situ Hybridization. USCAP Annual Pathology Meeting, Mod. Pathol. 1995; page 81A.
44. Ferreiro JA, Myers JL, **Bostwick DG**. Accuracy of Frozen Section in Diagnostic Surgical Pathology: One Year's Experience at the Mayo Clinic with 24,880 Cases. USCAP Annual Pathology Meeting, Mod. Pathol. 1995; page 157A.
45. Ferreiro JA, Grivold JJ, **Bostwick DG**. The Accuracy of Frozen Section in Diagnosis of Mammographically Directed Breast Biopsies: Results of 1,490 Consecutive Cases. USCAP Annual Pathology Meeting, Mod. Pathol. 1995; page 17A.
46. R. Schleicher R, Bandea C, Zhang M, Tan W, **Bostwick DG**, Hunter S, Varma V. Neurofilament mRNA is Downregulated in Prostatic Adenocarcinoma. USCAP Annual Pathology Meeting, Mod. Pathol. 1995; page 83A.
47. Kletscher B, Qian J, **Bostwick DG**, Zincke H, Blute ML, Barrett DM. Prospective analysis of the incidence of ipsilateral adrenal metastasis in renal cell carcinoma. *J Urol* 1995, 153:437A.
48. **Bostwick DG**, Larson T, Corica A. Pathological Comparison of Human Prostate between Treatment of Transurethral Laser versus Transurethral Microwave Thermal Therapy. 1996 American Urological Association (AUA) Annual Meeting, *J. Urol.* 1996; 153:231A.
49. Harmon WJ, Barrett DM, Qian J, **Bostwick DG**, Gokcen M. Transurethral Enzyme Ablation of the Prostate (TEAP): A Canine Model. 1996 AUA Annual Meeting, *J. Urol.* 1996; 153:399A.
50. Kletscher BA, Qian J, **Bostwick DG**, Zincke H, Blute ML, Barrett DM. Prospective Analysis on the Incidence of Ipsilateral Adrenal Metastasis in Renal Cell Carcinoma. 1996 AUA Annual Meeting, *J. Urol.* 1996; 153:547A.

51. Monda JM, Lauvetz RW, Qian J, ***Bostwick DG***, Husmann DA. Myoperitoneal Bladder Augmentations: The Incidence of Cancer and Bacterial Colonization in the Rat Model. 1996 AUA Annual Meeting, J. Urol. 1996; 153:476A.
52. Ferguson JK, Qian J, Husmann DA, ***Bostwick DG***. Increased Androgen Receptor Expression is Associated with Decreased Survival in Metastatic Prostate Cancer. 1996 AUA Annual Meeting, J. Urol. 1996; 153:483A.
53. Dundore PA, Blute ML, Farrow GM, ***Bostwick DG***. Subclinical Biochemical (PSA) Failure in Ninety Men 50 Years of Age and Younger with Prostate Cancer Treated by Radical Retropubic Prostatectomy. 1996 AUA Annual Meeting, J. Urol. 1996; 153:505A.
54. Gould VE, Doljanskaia V, Gooch G, ***Bostwick DG***. Molecular Stability of the Glycoprotein A-80 in Prostatic Adenocarcinoma Following Androgen Deprivation Therapy. USCAP Annual Pathology Meeting, *Mod. Pathol.* 1996; 9:73A.
55. Gould VE, Doljanskala G, Gooch G, ***Bostwick DG***. Immunolocalization of Glycoprotein A-80 in Prostatic Hyperplasia, Dysplasia, and Carcinoma. *Mod. Pathol.* 1996; 9:73A.
56. Lopez-Beltran A, Pacelli A, Farrow GM, ***Bostwick DG***. Carcinosarcoma of the Urinary Bladder: Clinicopathologic Study of 41 Cases. USCAP Annual Pathology Meeting, *Mod. Pathol.* 1996; 9:77A.
57. Lopez-Beltran A, Pacelli A, Qian J, Jenkins RB, ***Bostwick DG***. Atypical Adenomatous Hyperplasia of the Prostate: Immunophenotype, Genotype, and DNA Ploidy Analysis. USCAP Annual Pathology Meeting, *Mod. Pathol.* 1996; 9:77A.
58. MacLennan GT, Farrow GM, de Matteis A, ***Bostwick DG***. Renal Cell Carcinoma of Collecting Duct Type: A Report of 16 Cases. USCAP Annual Pathology Meeting, *Mod. Pathol.* 1996; 9:77A.
59. Qian J, ***Bostwick DG***, Jenkins RB. C-MYC Gene Amplification and Chromosomal Anomalies in Prostatic Intraepithelial Neoplasia and Stage D1 Carcinoma by Fluorescence In Situ Hybridization. USCAP Annual Pathology Meeting, *Mod. Pathol.* 1996; 9:81A.
60. Qian J, ***Bostwick DG***, Lieber MM, Jenkins RB. Chromosomal anomalies and c-myc oncogene amplification in stage D1 prostatic adenocarcinoma. *Mod Pathol* 1996; 9:81A.

61. Qian J, ***Bostwick DG***, Takahashi S, Borell TJ, Brown JA, Lieber MM, Jenkins RB. Comparison of Fluorescence In Situ Hybridization Analysis of Isolated Nuclei and Routine Histologic Sections of Prostatic Carcinoma. USCAP Annual Pathology Meeting, *Mod. Pathol.* 1996; 9:81A.
62. Shan A, Cunningham JM, qian J, McDonnell SS, ***Bostwick DG***, Thibodeau SN. Allelotyping of prostatic adenocarcinoma. *Proc of AACR* 1996, 37:551.
63. Jenkins RB, ***Bostwick DG***, Lieber MM, Qian J. An evaluation of c-myc oncogene amplification in whole-mount state D1 radical prostatectomy specimens by fluorescence in situ hybridization (FISH). *Proc of AACR* 1996, 37:551.
64. ***Bostwick DG***. Prostate Cancer and Androgen Deprivation, Reply. *CAP Today*, Vol. 10, August, 1996.
65. Waters DJ, Patronek GJ, ***Bostwick DG***, Glickman LT. Comparing the Age at Prostate Cancer Diagnosis in Humans and Dogs. *J. Natl. Cancer Inst.*, Nov 20, 1996; 88:1686–7.
66. Lauvetz RW, Monda JM, Tietjen DN, Qian J, ***Bostwick DG***, Husman DA. Mucosal inflammation and intravesical toxic oxygen radical concentration correlate to the rate of malignant transformation found in various augmentation cystoplasties. *J Urol* 1996, 155:483A.
67. Hirasawa K, Qian J, Pelloski C, Weiss M, Sebo TJ, ***Bostwick DG***, Lieber MM, Pisansky TM, and Jenkins RB. Trisomy 7 detected by fluorescence in situ hybridization (FISH) in needle biopsy is potential marker for the clinically localized prostate cancer relapse. *J Urol* 1996, 155:601A.
68. Kletscher B, Qian J, Blute ML, Zincke H, Thibodeau S, ***Bostwick DG***. Clonal origin of renal cell carcinoma. *J Urol* 1996, 155:542A.
69. Alexander EE, Qian J, Wollan PC, Myers RP, ***Bostwick DG***. Prostatic intraepithelial neoplasia does not appear to raise serum prostatic specific antigen concentration. *J Urol* 1996, 155:696A.
70. Waters DJ, ***Bostwick DG***, Qian J, Hayden DW, Sweet D, Hendrick MJ, Klausner JS, Bell FW. Skeletal Metastases in Dogs with Spontaneous Prostate Cancer. (Submitted to American Association for Cancer Research Meeting, 1997)
71. Qian J, ***Bostwick DG***, MacLennan GT, Brown J, Farrow GM, Jenkins RB. Detection of genetic changes in collecting duct carcinoma of the kidney by fluorescence in situ hybridization (FISH). *Mod Pathol* 1997, 1:85A.

72. Qian J, Jenkins RB, ***Bostwick DG***. Is the cribriform pattern of prostate cancer undergraded? A fluorescence in situ hybridization study of cribriform cancer and cribriform PIN in 25 whole mount prostates. *Mod Pathol* 1997, 1:86A.
73. Bock BJ, ***Bostwick DG***. Prostatic Peripheral Zone Adenocarcinoma Mimicking Ductal Adenocarcinoma: A Study of 17 Cases. *Mod Pathol*. 1997; 10:70A.
74. Iczkowski KA, ***Bostwick DG***, MacLennan GT. Atypical Small Acinar Proliferation of the Prostate Suspicious for Malignancy in Prostate Needle Biopsies: Clinical Significance in 33 Cases. *A. Jour. Surg. Path.* 1997 Dec; 21(12):1489–95.
75. ***Bostwick DG***, Bostwick KC. No Residual Cancer in Radical Prostatectomy Specimens: Incidence in 6,843 Cases from 1966 to 1995. *Mod Pathol*. 1997; 10:71A.
76. Cheng L, MacLennan GT, ***Bostwick DG***, Jacobs GH, Abdul-Karim FW. Paneth Cell Differentiation in the Benign Prostate. *Mod Pathol*. 1997; 10:71A.
77. Cheville JC, Reznicek MJ, ***Bostwick DG***. The Focus of Atypical Glands Suspicious for Malignancy in Prostate Needle Biopsy Specimens: Evaluation of Cases Seen in a Community Practice. *Mod Pathol*. 1997; 10:71A.
78. Chuaqui RF, Englert CR, Strup SE, Vocke CD, Zhengping Z, Duray PH, ***Bostwick DG***, Linehan WM, Liotta LA, Emmert-Buck MR. Comparison of Gene Expression in Microdissected Prostate Normal and Tumor Epithelium in a Patient with Clinically Aggressive Cancer. *Mod. Pathol*. 1997; 10:72A.
79. Dundore PA, ***Bostwick DG***. Aggressiveness of Prostate Cancer in Men Age 50 and under Treated by Radical Retropubic Prostatectomy. Comparison with Older Men Using PSA Failure as an Endpoint. *Mod Pathol*. 1997; 10:73A.
80. Egan AJM, ***Bostwick DG***. Prediction of Extraprostatic Extension of Prostate Cancer Based on Needle Biopsy Findings: Perineural Invasion Lacks Significance on Multivariate Analysis. *Am J. Surg. Path.* 1997 Dec; 21(12):1596–500.
81. Goldstein NS, ***Bostwick DG***. Histologic Type and Grade of Renal Cell Carcinoma: Clinical Significance in 813 Cases with Long-term Follow-up. *Mod. Pathol*. 1997; 10:76A.
82. MacLennan GT, Farrow GM, ***Bostwick DG***. Immunohistochemistry in the Evaluation of Renal Cell Carcinoma: A Critical Appraisal. *Mod. Pathol*. 1997; 10:81A.

83. Muir TE, Pacelli A, Farrow GM, ***Bostwick DG***. Mesonephric Remnants of the Prostate: Incidence and Clinical Significance. *Mod. Pathol.* 1997; 10:83A.
84. Orozco R, Schwob V, Bassler T, Egan A, O'Dowd G, ***Bostwick DG***. The Diagnosis of "Suspicious" for Adenocarcinoma in Prostate Biopsies: Evaluation of Follow-up Biopsies. *Mod. Pathol.* 1997; 10:84A.
85. Pacelli A, ***Bostwick DG***. Clinical Significance of Intestinal Metaplasia of the Urinary Bladder. *Mod. Pathol.* 1997; 10:84A.
86. Pacelli A, ***Bostwick DG***. The Clinical Significance of High-Grade Prostatic Intraepithelial Neoplasia in Transurethral Resection Specimens. *Urology.* 1997 Sept; 50(3):355–9.
87. Pacelli A, Lopez-Beltran A, Egan AJM, ***Bostwick DG***. Prostatic Adenocarcinoma with Glomeruloid Features. *Mod. Pathol.* 1997; 10:85A.
88. Qian J, ***Bostwick DG***, MacLennan GT, Brown J, Farrow GM, Jenkins RB. Detection of Genetic Change in Collecting Duct Carcinoma of the Kidney by Fluorescence In Situ Hybridization (FISH). *Mod. Pathol.* 1997; 10:85A.
89. Qian J, Jenkins RB, ***Bostwick DG***. Is the Cribriform Pattern of Prostate Cancer Undergraded? A Fluorescence In Situ Hybridization Study of Cribriform Cancer and Cribriform PIN in 25 Whole Mount Prostates. *Mod. Pathol.* 1997; 10:86A.
90. Wang X, Farrow GM, ***Bostwick DG***. Prostatic Stromal Hyperplasia with Atypia: A Study of 10 Cases. *Mod. Pathol.* 1997; 10:94A.
91. Qian J, Bostwick DG, Hirasawa K, Bergstralh E, Borell T, Lieber MM and Jenkins RB. C-myc amplification and loss of p53 detected by fluorescence in situ hybridization (FISH) predict survival in stage TxN1M0 prostate cancer. *Proc of AACR* 1997, 38:428.
92. Kletscher B, Qian J, Cunningham J, ***Bostwick DG***, Thibodeau S, Blute ML, Zincke H. Allelic instability on chromosome 3 in multifocal renal cell carcinoma. *J Urol* 1997, 157:276.
93. Hirasawa K, Qian J, ***Bostwick DG***, Lieber MM, and Jenkins RB. Loss of chromosome 18 detected by fluorescence in situ hybridization (FISH) is a prognostic marker for stage D1 prostate cancer. *J Urol* 1997, 157:349.
94. Qian J, Lee HK, Huang H, Hirasawa K, ***Bostwick DG***, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI, Jenkins RB. A Molecular Cytogenic Analysis of 7q31 in Prostate Cancer. American Association for Cancer Research Annual Meeting, 1998.

95. Qian J, Jenkins RB, ***Bostwick DG***. Determination of gene and chromosome dosage in prostate cancer and its precursors (presented in *International Symposium on Strategies for the Chemoprevention of prostate cancer*. Oct. 30-31, 1998. Brussels, Belgium.)
96. Iczkowski KA, Casella G, Seppala RJ, Jones GL, Mishler BA, Qian J, ***Bostwick DG***. Volume of prostate tissue sampled by sextant needle biopsy may influence detection rate for cancer. *Mod Pathol* 2002, 1:111A.
97. Iczkowski KA, Jones GL, Casella G, Qian J, ***Bostwick DG***. Variation in tissue sampled by sextant needle biopsy influences prostate cancer detection rate. *Mod Pathol* 2003, 1:165A.
98. Qian J, Burke HB, Hoang a, Ma J, ***Bostwick DG***. Using the Gleason Score as a prostate cancer prognostic factor: Leave seven alone. *Mod Pathol* 2003, 1:177A.
99. McCarthy RP, Zhang S, ***Bostwick DG***, Qian J, Eble JN, Cheng L. Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. *Mod Pathol* 2004, 1:166A.
100. Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, ***Bostwick DG***. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. *Mod Pathol* 2005, 1:146A.
101. Liu L, Qian J, Singh H, Meiers I, Tops T, Zhou X, ***Bostwick DG***. Separation of chromophobe renal cell carcinoma from oncocytoma and clear cell carcinoma: an optimal immunohistochemical panel for differential diagnosis. *Mod Pathol* 2006, 1:126A.
102. Lang K, Johnston J, Qian J, ***Bostwick DG***. Is microalbuminuria associated with prostate and bladder cancer? *Mod Pathol* 2006, 1:146A.
103. Meiers I, Singh H, Maramot K, Liu L, Qian J, ***Bostwick DG***. Improved filter method for urine sediment detection of urothelial carcinoma by FISH. *Mod Pathol* 2006, 1:150A.
104. Soltani MH, Lin L, Qian J, ***Bostwick DG***. Diagnostic utility of racemase (P504S)/34BE12/p63 antibody cocktail in the assessment of routine prostate needle biopsies. *Mod Pathol* 2006, 1:163A.
105. Hossain D, Meiers I, Qian J, MacLennan GT, Bostwick DG. Prostatic stromal hyperplasia with atypia: A benign, histologically worrisome lesion of the prostate. *Mod Pathol* 2007, 1:152A.

106. Qian J, Liu L, Ma J, Meiers, I, Lang K, Hewitt SM, Wilson TH, Rittmaster RS, **Bostwick DG**. The 5-alpha-reductase inhibitor dutasteride decreases relative cancer volume and induces multiple phenotypic changes in the human prostate. *Mod Pathol* 2007, 1:171A.
107. Wang X, Jones TD, Zhang S, Eble JN, **Bostwick DG**, Qian J, Lopez-Beltran A, Montironi R, Harris JJ, Cheng L. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. *Mod Pathol* 2007, 1:182A.
108. Lang K, Johnston J, Hossain D, Medina M, Singh H, Qian J, **Bostwick DG**. Incidence of polyomavirus infection in urine specimens from patients with positive FISH results. *Mod Pathol* 2008, 1:78A.
109. Ma j, Hull D, Singh H, Lang K, Qian J, **Bostwick DG**. Precursor of PSA (Pro-PSA) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. *Mod Pathol* 2008, 1:168A.
110. Crawford ED, Qian J, Drewnowska K, Varvel S, Wilk M, Mason L, Kaminetsky J, Huisman T, bilowus M, Freedman S, **Bostwick DG**. PCA3: A Urine-Based Genetic Assay for Detection of Prostate Cancer in Men with elevated PSA. *Mod Pathol* 2009, 1:154A.
111. Hull D, Jarmulowicz, MK, Ma J, Qian J, **Bostwick DG**. Topographic relationship of high-grade PIN with atrophy and adenocarcinoma. *Mod Pathol* 2009, 1:340A.
112. Qian J, Weber D, Hossain D, Liu L, **Bostwick DG**. Detection of chromosomal anomalies in chromophobe renal cell carcinoma using fluorescence in situ hybridization. *Mod Pathol* 2009, 1:342A.
113. **David G. Bostwick**, Pritpal Kochar, Deloar Hossain, David Hull, Deena Weber, Junqi Qian. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation are significant cancer risk factors: follow-up study of 1,476 cases. (American urologic association annual meeting, 2009.)
114. Junqi Qian, Deena Weber, Deloar Hossain, Lina Liu, **David G. Bostwick**. Detection of Chromosomal Anomalies in Chromophobe Renal Cell Carcinoma Using Fluorescence in situ Hybridization. *Modern Pathology*, A1548, P342A (US-Canadian Association of Pathology, annual meeting 2009.)
115. Qian J, Medina M, Crewell K, Weber D, Hossain D, **DG Bostwick**. Deletion of 9p21 is a Rare Finding in Urine Specimens Collected from Patients with a History of Hematuria and Bladder Cancer. (American Society of Clinical Oncology, ASCO, annual meeting 2009.)



116. Junqi Qian, Deena Weber, Richard Cochran, Deloar Hossain, **DG Bostwick**. Detection of Chromosomal Anomalies in Uterine Endometrial Carcinoma Using Fluorescence in situ Hybridization (UteroFISH™.) (American Society of Clinical Oncology, ASCO, annual meeting 2009.)
117. **DG Bostwick**, Deloar Hossain, Justin Peters, Junqi Qian. C-myc protein is a useful new diagnostic marker for prostate cancer. (College of American Pathologist annual meeting 2009.)
118. D Hull, D Hossain, J Qian, J Johnston, K Lang, M Medina, H Singh, **DG Bostwick**. (College of American Pathologist annual meeting 2009.)
119. D Hossain, H Singh, S Banerjee, J Qian, **DG Bostwick**. Cytological analysis of Residual Fixative from Prostate Biopsy Vials. (College of American Pathology annual meeting 2009.)
120. J Qian, D Hossain, G Sadasivan, **DG Bostwick**. Detection of chromosomal Anomalies in Colon Biopsy Specimens Using FISH (USCAP annual meeting 2010.)
121. D Hossain, J Qian, J Adupe, K Drewnowska, S Varvel, M Wilk, **DG Bostwick**. Differential Diagnosis of Melanomas Using Fluorescence in situ Hybridization (FISH) – MelanoFISH. (USCAP 2011 annual meeting.)
122. D Hossain, J Squire, M Yashimoto, **DG Bostwick**. Application of four color fluorescence in situ hybridization identifies genomic deletion of the PTEN gene in 384 of 2115 (18.2%) diagnostic prostate cancer-positive needle cores. (AUA 2013.)
123. **DG Bostwick**, H Singh, D Hossain. PTEN Losses by Fluorescence In Situ Hybridization (FISH) – but Not Immunohistochemistry – Correlate with Higher Gleason Grade: Prospective Study of 2261 Prostate Needle Biopsies in a Community Practice Setting. (USCAP 2013.)
124. **DG Bostwick**, N Valkov, R Voyles, M Kulikowski, D Hossain. Acid Hematoxylin is an Alternative to Feulgen Staining for Cytology Specimens and DNA Ploidy Analysis. (USCAP 2013.)
125. **DG Bostwick**, D Hossain, E Turbat-Herrera, P Schlosshauer. Diagnostic Clinical Application of Multi-Target Fluorescence *In Situ* Hybridization in Endometrial Biopsies: Prospective Study of 282 Cases. (USCAP 2013.)
126. **DG Bostwick**, D Hossain. Accuracy of an Oligonucleotide-Based Fluorescence In Situ Hybridization (FISH) Urine Assay: Prospective Study of 389 Patients Monitored for Recurrence of Bladder Cancer. (USCAP 2013.)

127. D Hossain, ***DG Bostwick***. Loss of Chromosome 10 (Monosomy) is Associated with High Gleason Grade in Prostate Cancer: A Study of 10 Cases. (CAP annual meeting 2013.)
128. D Hossain, F Kalantarpour, ***DG Bostwick***. Application of Four Color Fluorescence in Situ Hybridization Identifies Genomic Deletions of the PTEN Gene in 464 of 2465 (18.8%) Diagnostic Prostate Cancer-Positive Needle Cores: (CAP Annual Meeting 2013.)
129. D Hossain, F Kalantarpour, R Maitlen, S King, ***DG Bostwick***. Categorization of PTEN Tissue FISH Insufficiency in Prostate and Bladder Biopsies: Experience with 6537 Consecutive Cases:
130. D Hossain, F Kalantarpour, G Montalvo, ***DG Bostwick***. High Risk HPV (other than HPV 16 and 18) and Cervical Intraepithelial Lesions: Correlation Between Genotype and Dysplasia. (CAP annual meeting 2013.)
131. D Hossain, F Kalantarpour, S Groen, ***DG Bostwick***. Can Tissue Slides from Failed PTEN Gene Detection by FISH be Salvaged for PTEN Protein Detection by IHC? (CAP annual meeting 2013.)
132. D Hossain, F Kalantarpour, G Montalvo, ***DG Bostwick***. High Risk HPV Genotypes Other than Genotype 16 and 18 are Much More Prevalent in the Community. (CAP annual meeting 2013.)
133. ***DG Bostwick***, F Kalantarpour, D Hossain: Acid Hematoxylin Stain Decreases Incidence of “Atypical” Urine Cytology. (CAP annual meeting 2013.)
134. F Kalantarpour, D Hossain, R Maitlen, S King, ***DG Bostwick***. Frequency of 3q26.2 (TERC Gene) and 5p15.2 (CTNND2 Gene) Amplification in Low Grade Cervical Intraepithelial Neoplasia: FISH-based Study of 301 Cases. (CAP annual meeting 2013.)
135. F Kalantarpour, D Hossain, ***DG Bostwick***. Comparison of Pathological Findings in Conventional Punch Biopsy and Spira Brush™ in 2000 Consecutive Cervical Biopsies (1000 with each method). (CAP annual meeting 2013.)
136. F Kalantarpour, D Hossain, S Groen, P Garcia, ***DG Bostwick***. Correlation of PTEN and PAX2 Protein Loss by Immunohistochemistry with Cytological Atypia in Tissue Obtained by Endometrial Tao Brush. (CAP annual meeting 2013.)
137. F Kalantarpour, D Hossain, ***DG Bostwick***. Placental Site Nodule of the Uterus: Clinicopathological Study of 103 Cases. (CAP annual meeting 2013.)

138. F Kalantarpour, D Hossain, ***DG Bostwick***. Comparison of Pathological Findings in Pipelle and Tao Brush: Study of 2000 Consecutive Endometrial Biopsies (1000 from each Method.) (CAP annual meeting 2013.)
139. X Zeng, ***DG Bostwick***. Correlation of Urinary B<sub>2</sub>-microglobulin with Kidney Injury Molecule-1 Staining in Renal Biopsy. (Kidney Week 2014/American Society of Nephrology).